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Abstract

Discrete arginine topologies guide escape of miniature proteins
from early endosomes to the cytoplasm.
Jacob S. Appelbaum
2012
Polypeptides and peptide mimetics sample a wide chemical space with broad potential
to modulate cellular function, but their application to cytoplasmic targets is limited be
cause when added to cells their cytosolic concentration remains low. This limitation is
due to a diffusion barrier (the plasma membrane) and absence of dedicated import ma
chinery. Highly cationic peptides and proteins sometimes gain cytosolic access, but how
they do so is not well understood. Using a small library of cationic miniature proteins, I
probe the influence of positive charge number and orientation on the ability the minia
ture protein to access the cytoplasm. Using a novel assay, I identify a cationic miniature
protein, which we called 5.3, that carries a discrete arginine motif and efficiently reaches
the cytoplasm. Database searches find that the precise motif identified (an arginine
present in positions i, i + 4, i + 7, i + 10, and i + 11 of an a-helix) is not present in na
ture, but that similar motifs are present in natural proteins that interact with cellular
membranes. Finally, I examine the cellular pathway by which 5.3 reaches the cytoplasm.
I find that this miniature protein enters the cell via a dynamin and cholesterol depen
dent endocytic mechanism and is delivered to Rab5+ early endosomes. In contrast to
the shiga-like toxins, and many non-enveloped viruses (which escape to the cytoplasm
from the endoplasmic reticulum) as well as other peptides previously identified as 'cell
penetrating', only 5.3 escapes from early endosomes. These findings should enable the
future dissection of the precise molecular events underlying cytoplasmic access of pep
tides and proteins, and may illuminate principles for the engineering of peptides and
peptidomimetics that access cytoplasmic targets.
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Chapter i

Introduction
Permeability barriers presented by lipid bilayers
Without the ability to separate their contents from the outside world, cells could not be
considered 'alive'. The cellular limiting membrane, a phospholipid bilayer, is critical to
the concentration of metabolites, generation and use of energy, segregation of genetic
material, and sequestration of harmful digestive enzymes or poisons. At the same time,
lipid bilayers represent frustrating barriers to the physician or biologist wishing to per
turb the inner workings of a cell for the purposes of scientific experiment or therapeutic
gain.
The high resistance presented by lipid bilayers is well known in the field of neurobi
ology, where the increase in conductance due to the opening of single ion channels can
be recorded[i]. This is only possible because the membrane (in this case, along with its
seal to the recording pipette) prevents the crossing of small ions, resulting in a resistance
of 109 — 10110, which, given a thickness of -5 nM makes the lipid membrane one of the
most resistive materials known(p ~ 10190 • m, teflon is ~10220 • m, air is ~10160 • m).
The efforts of physicians and chemists to identify useful drugs has also been a de
facto investigation of the permeability barrier presented by cell membranes. While many
drugs act on protein receptors on the cell surface, for drugs to act on intracellular targets,
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they must reach the cytoplasm. The many examples of bioactive materials, along with
the negative examples provided by their inert counterparts, has led to a set of guidelines
for the design of small molecules that are readily absorbed and reach the cytoplasmic].
These guidelines include a limit on molecular size (<500 Da), polarity (logP > 5), and
hydrogen bonding potential ( < 10 H-bond acceptors, <5 H bond donors). Thus the lim
itations of membrane permeability have designated a large fraction of potential chemical
compounds as unlikely to be useful.
This limitation has particularly frustrated efforts to manipulate protein protein inter
actions within cells. These interactions take place over flat surfaces, generally >6ooA2,
often being between 1000-2500A2, and thus difficult to target with small molecules. In
addition, prediction of key residues within the protein-protein interface is a challenge^].
While the characteristic physicochemical properties of protein interfaces vary, many con
tain key polar residues^]. In fact, within the many residues that form a protein-protein
interface, stabilizing binding energy often results from only several residues (termed 'hot
spots' [5, 6]) chosen from within a subset of amino acids: phenylalanine, tyrosine, tryp

tophan, arginine, and isoleucine are over-represented[6]: Small molecules are not well
suited to achieve specific binding to flat and sometimes polar surfaces.
Peptides and proteins on the other hand are very well suited to the modulation of
protein-protein interactions^]. By using a peptide that exhibits a well-defined structure
in solution, the entropic cost associated with a concerted binding/folding event can be
paid 'up front'[8, 9, 10], increasing the magnitude of the free energy of binding. While
important advances in the design of small molecule inhibitors based on the crystal struc
tures are being made[n, 12], accurate results are often only achievable as comparisons
between structurally similar small molecules[i3], and de novo identification of high affin
ity protein ligands has been difficult^, 12]. The situation for peptides is very different.
Protein epitope grafting[i4, 15, 16], wherein the interacting side chains of a protein or
peptide ligand are grafted onto a well folded a-peptide domain[i7,15, 18,19, 20, 21, 22]
or ^-peptide helix[23, 24, 25, 26, 27, 28] enables the facile creation of high affinity ligands.
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Peptides with low micromolar affinities can be isolated from small, designed libraries,
often containing only a dozen or so members[i5]. In the case of naturally encoded
a-peptide miniature proteins, ligand affinity can be improved via phage display[29],
in the case of non-natural ^-peptides, selection can be accomplished from bead-based
libraries[3o]. If the molecules thus selected could be engineered to reach their cytoplas
mic targets, a large selection of rapidly designable active chemical entities would likely
become available, enabling scientists and physicians to modulate cytoplasmic proteinprotein interactions for the purposes of interrogating function or ameliorating disease.
Those seeking to engineer cytoplasmic access into peptides and proteins may take
notice of the fact that pathogens have envolved to achieve the same result for different
ends: the debilitation and exploitation of a suitable host. The viral life cycle requires
cytoplasmic machinery for the replication of the viral genome[3i]. Anthrax and tetanus
toxins cleave synaptobrevin to inhibit neuronal transmission incapacitating the host[32].
Shiga and shiga-like toxins from E. coli enter cells of the colon and halt protein synthesis
leading to cell death and dysentery[33, 34]. The mammalian immune system has also
evolved specialized cells (antigen presenting cells, APCs) that internalize extracellular
protein into the cytoplasm^]. Cytoplasmic proteolysis pathways generate peptides
that are loaded onto peptide binding proteins (the major histocompatability complex,
MHC) which are then displayed on the cell surface for interrogation by T cells[36, 37,
38]. A better understanding of the pathway by which APCs internalize extracellular
protein could very likely be exploited for the purposes of vaccine development^, 40],
or engaging the immune system to help fight tumors[4i].
I've taken both a top-down and bottom-up approach in seeking to better define the
design principles the enable the cytoplasmic access of small miniature proteins. First,
using a strategy developed in the Schepartz Lab for the monitoring of protein-protein in
teractions, I examine the requirements for peptide-MHC association. Next, using a small
library of cationic miniature proteins, I probe the influence of positive charge number
and orientation on the ability the miniature protein to access the cytoplasm. Using a
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novel assay, I identify a cationic miniature protein, called 5.3, carrying a discrete arginine
motif that efficiently targets miniature proteins to the cytoplasm. Database searches find
that the precise motif identified (an arginine present in positions i, i + 4, i + 7, i + 10,
and i + 11 of an a-helix) is not present in nature, but that similar motifs are present in
natural proteins that interact with cellular membranes. Finally, I examine the cellular
pathway by which 5.3 reaches the cytoplasm. I find that this miniature protein enters the
cell via a dynamin and cholesterol dependent endocytic mechanism and is delivered to
Rab5+ early endosomes. In contrast to the shiga-like toxins, and many non-enveloped
viruses (which escape to the cytoplasm from the endoplasmic reticulum) and other pep
tides previously identified as 'cell penetrating', only 5.3 escapes from early endosomes.
These findings should enable the future dissection of the precise molecular events un
derlying cytoplasmic access of peptides and proteins, and may illuminate principles for
the engineering of peptides and peptidomimetics that access cytoplasmic targets.
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Chapter 2

Use of Bipartite Tetracysteine
Display to Probe the Association of
Cross-Presented Peptides with the
Major Histocompatability Complex
2.1 Background
The mechanistic xmderstanding of biological processes increasingly requires atomic level
resolution of changes in protein conformation or association state. Recent results suggest
that cells localize signaling processes on discrete membrane[42] or endosomal[43] regions
creating a diversity of protein conformations segregated in space. In addition it has
long been known that taking protein systems out of their natural context can result in
experimental artifacts. Therefore researchers require the ability to interrogate changes in
proteins within a cellular environment using a method that provides resolution within
time and space. Very few, if any, existing methods can satisfy these demands, and thus
new techniques for the interrogation of protein-protein, or protein-peptide interactions
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withirv living cells are required.
Antigen presentation is the process which integrates the responses of innate and
adaptive immune cells to generate an immune response, and provides a case-in-point
for the above requirements. The process takes place across cellular contacts between spe
cialized antigen presenting cells (APCs) and T cells through the interaction of the major
histocompatibility complex (MHC) glycoprotein on the APC and the T cell receptor on
the T lymphocytes. While the presence of cytokines in the surrounding media as well
as the expression of surface 'costimulatory' proteins on the APC can influence the vigor
with which the T cells responds, the primary factor that determines activation of the acti
vation of cytotoxic T lymphocytes (CTL) is the tight association of the T cell receptor with
a complex composed of the class I MHC molecule (MHC-x) and an antigenic peptide.
Antigenic peptides are derived from proteolytic fragments of proteins both expressed
in the cytoplasm (endogenous) and internalized (exogenous). Endogenous antigens are
complexed with MHC-i through specialized chaperones in the endoplasmic reticulum,
but the mechanism by which exogenous peptide antigens are loaded onto MHC-i re
mains unknown.

2.1.1

The spatial requirements of antigen presentation.

All nucleated mammalian cells utilize the 'classical' MHC-I loading pathway to present
endogenous antigen for CTL surveillance. Proteins targeted for degradation by polyubiquitination are cleaved by the proteasome into oligopeptides that are transported into
the endoplasmic reticulum (ER) by the transporter associated with antigen processing
(TAP). In the ER, chaperones mediate association of peptide with MHC-i and the result
ing peptide-MHC-i complexes are transported to the cell surface for display [38].
The presentation of exogenous antigen by MHC-I on the APC surface (a process
called cross-presentation [44, 45, 46]) presents several conundrums. Perhaps the most
significant is whether exogenous protein antigen must access the cytoplasm for protea-
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somal degradation. If exogenous proteins do reach the cytoplasm of APCs, presentation
of derived peptide antigens could proceed in the usual fashion. In the absence of specific
import machinery, cytoplasmic access of exogenous proteins would represent a severe
exception to the permeability barrier of the cell.
At least five distinguishable pathways have been proposed to explain the mechanism
by which MHC-i molecules acquire exogenous peptide antigen[47, 36]. The simplest (A)
involves digestion of endocytosed protein in peripheral vesicles that then fuse with re
cycling endosomes [48] or more acidic compartments (such as the MHC class II loading
compartment [49]) that catalyze the exchange of antigenic peptide loading on MHC-i
before transport back to the cell surface. Alternatively, peptides [50] delivered to the
cytosol, either by (B) endosomal escape or (C) gap junctions[51] could be imported into
the ER by TAP and loaded via the 'classical' MHC-i pathway. The two remaining path
ways involve delivery of intact protein to the cytosol via Sec6i. Phagosome-ER fusion
(D) may deliver extracellular proteins to the ER; the proteins are then retro-translocated
to the cytosol for proteosomal degradation^]. A similar process (E) could occur in pe
ripheral endosomes that contain Sec6i and TAP, but are distinct from the endoplasmic
reticulum[52].
The challenge in understanding the formation of exogenous peptide-MHC complexes
is made more difficult by the variety of complexes present, the need for accurate subcel
lular localization and the small size (but critical nature) of the peptide in comparison to
the MHC molecule. In addition, it is the combination of peptide and MHC that must
be recognized, because the peptides in isolation are inert, and because APCs continually
express, internalize, and degrade multiple alleles of MHC, with some MHC molecules
being reloaded and recycled to the cell surface.
Identification of the compartment in which cross-presented peptide MHC complexes
first form would provide a way to distinguish experimentally between these hypotheses:
pathways B, C, and D predict that cross-presented MHC-peptide complexes should as
semble in the ER, whereas pathways A and E do not. Pathways A and B are proteosome-
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Figure 2.1: Pathways of Cross-presentation, (a) Endocytosed protein is degraded in pe
ripheral vesicles creating peptides that encounter empty MHC molecules. The exogenous
antigen does not enter the cytoplasm, (b) Peptides are delivered to endosomes and then
to the cytosol. The mechanism of peptide escape from endosomes has not been deter
mined. (c) Peptides from nearby cells are delivered to the cytoplasm directly via gap
junctions, (d) Phagosome-ER fusion delivers endocytosed protein to the ER. Protein is
retrotranslocated to the cytoplasm and is degraded by the proteasome. (e) Phagosomes
retrotranslocate protein to the cytoplasm, and re-internalize proteasomal peptides for
MHC-i assembly. No communication with the endoplasmic reticulum is required.
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independent, and should not be inhibited after addition of the proteasome inhibitor
bortezamib. Only model A is TAP-independent. Finally, only pathway D predicts that
intact protein antigen should exist in the ER. While experimental evidence for each of
these pathways has been observed in various cell line and mouse models, the direct
(or indirect) visualization of peptide-MHC complexes in the ER or in the peripheral endomembrane system has not been achieved. Knowledge of dominant pathways could
guide development of drugs specifically targeted to blocking presentation of autoantigens, without affecting the rest of the immune system.

2.1.2

Existing approaches to probe protein-protein interactions and their ap
plication to cross presentation.

Attempts at antibody-based immunolocalization of cross-presented peptide-MHC com
plexes have failed[53, 54, 55, 56]. An alternative common approach to studying the
subcellular localization of molecules is to tag them with fluorophores synthetically. New
small organic fluorophores that (with specialized microscopes) provide sub-diffraction
(i.e. 'super'resolution) are available^]. Covalent attachment of these dyes could pro
vide information on the proximity of peptides derived from exogenous antigen to MHCx but even super-resolution experiments are limited to -20 nm[58], which may define a
peptide and MHC molecule being localized to the same membrane region, but may leave
ambiguous whether they are complexed together.
Forster resonance energy transfer (FRET) operates on smaller distance scales (1-10
run) but requires tagging both interacting partners with fluorescent chromophores [59].
Antigenic peptides are small (8 - xx amino acids), and attaching a fluorescent protein
(GFP is 238 amino acids) to MHC near near its binding site may perturb the loading
process; placing a fluorescent protein on the C-terminal tail of MHC does not perturb
function, but locates the fluorescent protein far from the peptide preventing the possi
bility of FRET. New methods for detecting protein-protein interactions that rely of the
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physical association of proteins (protein complementation assays, see [60]) are being de
veloped, but these require the cooperative folding of protein and peptide to form single
domains in trans.
Tagging only the peptide with smaller fluorophores, such as fluorescein will not lead
to specific detection of MHC-peptide complexes; all of the peptide within a cell would be
fluorescent. Small solvatochromatic fluorophores have been incorporated as side chains
of unnatural amino acids within peptide MHC II ligands[6i]. These molecules show
fluorescence enhancement when buried in the MHC-peptide binding groove, but the
specificity of the signal in this case was not demonstrated. In addition these molecules
showed a fluorescence enhancement roughly two-fold above background, a level not
high enough to permit microscopic examination of the cells.
Previous attempts to visualize the formation and trafificking of cross-presented peptideMHC complexes have been thwarted by the inability of fluorescently labeled antibodies
to detect specific complexes within live cells [55]. Bipartite tetracysteine display possesses
unique advantages in this regard, as (1) it requires only a 4 amino acid tag, (2) binding
is rapid, allowing pulse chase experiments, (3) the complex formed with FlAsH/ReAsH
possesses high thermodynamic and kinetic stability[62], and ReAsH (4) can polymerize
diaminobenzidine, enabling detection by electron microscopy (EM)[63, 64, 65]. Applying
bipartite tetacysteine display to the detection and localization of peptide-MHC com
plexes should reveal the cellular localization of cross-presented peptide-MHC complexes
with high resolution.

2.2 Results
The laboratory of Roger Tsien has previously shown that recombinant proteins contain
ing the linear tetracysteine sequence CCPGCC can be selectively labeled with the cell
permeable 'pro-fluorescent' molecules FlAsH (4,5-bis(i,3,2-dithiarsolan-2-yl)fluorescein)
and ReAsH (4,5-bis(i,3,2-dithiarsolan-2-yl)resorufin)[66, 63, 64, 67]. FlAsH and ReAsH
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are not fluorescent

on their own, but become so when bound to peptides or proteins

containing a tetracysteine motif[66]. In developing a strategy called bipartite tetracys
teine display, the Schepartz Lab split the tetracysteine tag between two proteins so that a
tetracysteine binding site is reconstituted upon protein protein interaction, but not when
the two proteins remain in isolation. Treating protein complexes with FlAsH or ReAsH
resulted in fluorescence

increases, but no increase was observed when mutations were in

troduced that prevented protein-protein interaction [62]. This strategy provides specific
advantages in cellular imaging. First the molecular recognition of the tetracysteine bind
ing site by ReAsH requires the cysteine residues to be 5-8 A apart (see below), delivering
spatial resolution that is unachievable by other means in cells. It also does not require
the genetic fusion of large fluorescent proteins, and removes the permeabilization step
necessary in immunofluorescence[66, 63, 64]. To extend this approach to peptide-MHC1 recognition, I began by generating a series of peptides and matched MHC-i variants
that contain judiciously placed dicysteine pairs. I then tested the ability of these MHC-i
variants to traffic to the cell surface and to bind to cysteine containing peptides.

2.2.1

A bipartite tetracysteine display strategy to selectively label peptideMHC-i complexes.

The original report of the use of bisarsenical profluorescent molecules to label recom
binant proteins assumed a target peptide CCRECC was helical[67]. Modeling a well
structured a-helix suggested that the thiol-arsenic bonds would be placed within the
proximity required to form a tetradentate binding site with the bisarsenical fluorophore.
Subsequent optimization of the ligand peptide sequence[68], and the determination of
the structure of the optimized peptide-ReAsH complex[69] by NMR reveals that the bis
arsenical fluorophore

prefers a hairpin structure (Fig. 2.2a). Analysis of the sulfur-sulfur

bond distances, as well as the distances between jS-carbons is shown (Fig 2.2b). The
intra-atomic distances range from -4-7 A for the sulfur atoms, and -5-8 A for the peptide
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^-carbons. This analysis confirms earlier hypothesestyo, 62, 63, 64, 67] that the forma
tion of a tetracysteine binding site, whether linear or bipartite, requires sub-nanometer
approximation of the four cysteine residues.
The first structure reported of the human leukocyte antigen (HLA) was of the A2
allelejyi, 72], which has served as a model for MHC-peptide loading. In silico muta
genesis of these complexes to introduce potential FlAsH/ReAsH binding sites suggests
two positions - 179 and 183 oh HLA-A2 - as ideal for the requisite Cys-Cys pair: the acarbons of these side chains are located approximately 6 A from each other and 6 A from
the two cysteines in the peptide YLLCCNYKL, which binds HLA-A2 with high affinity
(KD = 2 nM) [73, 74]. The a-carbon of other amino acids located within the a-helices that
border the peptide binding groove were also closely approximated to the a-carbons on
the bound antigenic peptide. These include R89, K90, A93, V97, Tioo, K170, A174, and
A182. We searched online databases^] for other cysteine pair-containing peptides that
bind HLA-A2 with high affinity. Identified ligands include IIITCCLLSV (KD = 6.3 nM)
and MICCDSRIW (KD = 24.6 nM). Pairing selected HLA-A2 variants with peptides
containing C2 pairs in different locations along the peptide binding groove should al
low for examination of the proximity requirements for the formation of a bipartite

C4

motif between the MHC variant and peptide. For example, I predict that K90C/A93C
and Y183C/T187C should form a suitable FlAsH/ReAsH binding motif in combination
with IIITCCLLSV or MICCDSRIVV, respectively. Additional sites on HLA-A2 suitable
for C2 installation are shown in figure 2.2d. Wild type HLA-A2 modified with an intact
tetracysteine (C4) tag serves as a positive control whose ability to bind FlAsH or ReAsH
should be independent of added peptide. Wild-type HLA-A2 lacking a C2 motif serves
as a negative control.
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2.2.2

Expression analysis of generated MHC-i Variants

I took note of the fact that the insertion of cysteine residues within the MHC heavy chain
may not be innocuous to the function of the protein. During the synthesis of MHCi, nascent proteins are tightly complexed with chaperones in the ER[77, 78]. Release
from the ER requires proper folding (for which peptide loading is a prerequisite^]),
and so the presence of MHC-i on the surface of cells implies that these molecules are
folded properly and loaded with peptide[8o, 81]. Wild-type HLA-A2, when tagged with
GFP and expressed in cultured epithelial cells, is present both at the surface and within
intracellular vesicles[49]. To determine whether the introduction of cysteines near the
peptide binding groove induced perturbations to the subcellular localization of MHC-i,
we expressed GFP fusions of dicysteine containing HLA-A2 variants in HeLa cells and
examined the cells by microscopy (Fig. 2.3).
HeLa cells were transfected with wild-type HLA-A2 tagged to GFP (HLA-A2-GFP)
or variants containing engineered dicysteines. The presence of expressed HLA-A2 was
determined by the observation of GFP fluorescence. To determine whether the trans
fected HLA-A2 variants were present on the cell surface, transfected cells were labeled
with phycoerythrin (PE) conjugated BB7.2, a monoclonal antibody specific for the folded
conformation of HLA-A2. As can be seen in figure 2.3b, HeLa cells transfected with wild-

Figure 2.2 (following page): A bipartite tetracysteine-based strategy to detect peptideMHC complexes, (a) The structure of ReAsH bound to the peptide sequence FLNCCPGCCMEP, as determined by NMR (personal communication from RY Tsien). (b)
The ReAsH molecule from a, shown without the peptide, but with bound thiol and
/5-carbon (above) or only bound thiol (below) ligands. The distances between jS-carbons
and between sulfur atoms is shown, (c) The structure of the peptide binding groove
of HLA-A2[y6] as determined by X-ray crystallography (PDB structure 1JHT). The sites
of cysteine incorporation are shown, (d) The combination of variants made. Each vari
ant contains two engineered cysteine residues, (e) Possible orientations of tetracysteine
motifs generated upon peptide binding. Each possible tetracysteine site is shown in a
different color. None of the distances shown are > 10 A from a-carbon to a- carbon, (f)
A close up view of tetracysteine site 1 (shown in e). The inter-/S-carbon distances are
shown. This view is rotated 180° from the view in e in order to better illustrate the close
apposition of the peptide with the a-helix that forms the peptide binding grove.
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Position # Residue #
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R89/A93 + E97Q I K90/A9B
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Figure 2.3: Epifluorescence microscopy showing the subcellular distribution of GFPtagged dicysteine containing HLA-A2 variants, (a) Experimental Schema. HeLa cells are
transfected with wild-type HLA-A2 tagged to GFP (HLA-A2-GFP) or HLA-A2 variants
containing engineered dicysteines. Cells are then stained with BB7.2-PE, an antibody that
recognizes folded HLA-A2[82], without permeabilization. The presence of red fluores
cence on the cell surface indicates the presence of properly folded HLA-A2, which when
overlapped with green can appear yellow. Variants of HLA-A2-GFP that express but do
not fold, may be retained in the ER or golgi, and should not lead to red surface staining
with BB7.2-PE. Some variants of HLA-A2-GFP may be unstable and rapidly degraded.
In this case, neither green nor red fluorescence will be observed, (b) Cell micrographs
prepared as described in a. Wild-type HLA-A2-GFP is expressed intracellularly and on
the cell surface after transfection in HeLa cells. R89/A93, K90/A93, Q179/A182, and
K170/A174 variants also express on the cell surface. Surface expression of Q179/Y183 is
low. The expression of the V79/T100 variant is undetectable.
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type HLA-A2-GFP display both green intracellular fluorescence

and red fluorescence

on

the cell surface. This is indicative of the proper folding and surface expression of the
transfected HLA-A2 allele. Cells transfected with A2 variants containing engineered dicysteines at positions R89/A93 or Q179/A182 show patterns of intracellular and surface
expression that are qualitatively similar to wild-type. HeLa cells transfected with an A2
variants containing engineered dicysteines at either positions K170/A174 or Q179/Y183
show both intracellular GFP and surface BB7.2 labeling, but increased green fluorescence
signal is located within the intracellular reticular network, indicating the possibility of
inefficient folding. The A2 variant containing dicysteines at position V79/T100 shows no
GFP fluorescence or BB7.2-PE labeling, indicating that this variant is not expressed.
To quantitatively assess whether A2 variants showing surface expression by mi
croscopy are present at levels similar to wild-type, HeLa cells transfected with wildtype HLA-A2-GFP or dicysteine containing variants were labeled with BB7.2-PE and
examined by flow cytometry (fig 2.4). Living cells were identified by their characteris
tic pattern of forward scatter (FSC) and side scatter (SSC), and their ability to exclude
propidium iodide. GFP expressing cells were identified by the presence of green flu
orescence and their levels of surface BB7.2 staining were compared. As can be seen
in figure 2.4b, HeLa cells transfected with wild-type HLA-A2-GFP show high levels of
surface BB2.7 staining (green line), but untransfected cells (black line) and cells not ex
posed to the antibody (grey shaded histogram) do not, confirming that HeLa cells are
HLA-A2-negative[83] in the absence of transfection, and that transient transfection in
duces surface A2 expression. Comparing the histograms shown in figure 2-4c-g to the
histogram in figure 2.4b shows that HeLa cells transfected with variants containing en
gineered dicysteines at sites R89/A93, K90/A93, K170/A174 and Q179/A182 express
surface levels of HLA-A2 that are similar to levels obtained for the wild-type allele.
HeLa cells transfected with HLA-A2 containing an engineered dicysteines at position
Q179/Y183 show either reduced surface expression or reduced antibody binding. (The
latter is a possibility, because the BB7.2 epitope is composed of the C-terminus of the «2-
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Figure 2.4: Surface expression of dicysteine containing HLA-A2 variants as assessed
by flow cytometry. HeLa cells transfected with HLA-A2-GFP or dicysteine containing
variants were stained with BB7.2-PE as shown in figure 2.3 before analysis by flow, (a)
Process of analysis. Cells were gated on forward scatter (FSC) and side scatter (SSC)
to define a 'live cell' population. Cells from the FSC/SSC gate were examined for GFP
expression and propidium iodide uptake. Cells there were PI- (live) and GFP positive
were selected for inclusion in the histograms shown in b. (b-g) The cell fluorescence due
to BB7.2-PE staining of GFP+ cells (green line) is compared to cells transfected with GFP
and treated with PI (PI-), black line, as well as untransfected cells, not treated with PI
(gray shaded histogram).
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helix, wherein Q179 and Y183 are located, and portions of its underlying ^-strand[84].)
This analysis confirms the conclusions following analysis by epifluorescence microscopy,
namely, that the introduction of dicysteines at positions R89/A93, K90/A93, K170/A174
and Q179/A182 do not severely perturb the expression, folding, or transport of HLA-A2
molecules. The same may also be true for the A2 variant with the dicysteine introduced
at position Q179/Y183.

2.2.3

Recognition of tetracysteine motifs within oxidizing cellular environ
ments.

The binding of ReAsH or FlAsH to peptide tetracysteine motifs requires arsenic-thiol ex
change. Because FlAsH and ReAsH will not react with oxidized disulfides[85], the tetra
cysteine must be completely reduced. Were the above dicysteine containing HLA-A2
variants to assemble with dicysteine containing peptides, the reconstituted tetracysteine
motif would be present within the lumen of the endoplasmic reticulum, an oxidizing en
vironment that promotes disulfide bond formation[86]. The addition of small thioalkanes
can reduce intralumenal thiols [87] revealing tetracysteine motifs for FlAsH and ReAsH
labeling[64]. In fact, careful choice of reductant can allow for pulse chase experiments,
distinguishing tetracysteine motif-containing proteins that are sensitive to cell permeant
versus cell impermeant reductants, or those that are located within reducing vs oxidizing
environments^].
To determine whether I could detect ER lumenal tetracysteine containing proteins,
I transfected HeLa cells with an expression vector encoding the HLA-A2 amino acid
sequence with the peptide sequence CCPGCC prepended to the N-terminus (C4-HLAA2-GFP). This C4-HLA-A2 should display labeling with ReAsH that is independent on
the formation of a bipartite tetracysteine motif composed of MHC and peptide. To con
firm that treatment with reducing agents could lead to the successful labeling of a tetra
cysteine motif present within the lumen of endosomes, these cells were treated with
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b
C4-HLA-A2-GFP

ReAsH

C4-HLA-A2-GFP +
ReAsH

* Image enhanced with 'unsharp mask'

Figure 2.5: Detection of tetracysteine motifs within oxidizing environments. HLAA2 was tagged on the N-terminus (within the ER lumen) with the peptide sequence
CCPGCC. (a) Labeling schema. HeLa cells were transfected with C4-HLA-A2-GFP for
24 hr before treatment with 1 }iM ReAsH, 10
EDT, and 10 mM TBP for 20 min.
Cells were then washed with HBSS and incubated for 20 min with 100 jiM EDT and 10
mM TBP to reduce non-specific ReAsH labeling before imaging by epifluorescence mi
croscopy. (b) Images of a HeLa cells transfected with C4-HLA-A2-GFP and labeled with
ReAsH as described in a. Fluorescence due to GFP is shown in green, while fluorescence
due to ReAsH is shown in red. An overlay of the two images is shown on the right,
where overlap of the green and red signals appears yellow. In the periphery of the cell,
the red ReAsH signal is concentrated in regions of GFP fluorescence. A zoomed image
of the region within the white box is shown below.
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ReAsH and 10 mM tributylphosphine (TBP), a cell permeable reducing agent previously
shown to reduce thiols present within the golgi lumen[64]. In addition, 10 ^M ethanedithiol (EDT) was included in the labeling mixture as a competitor for the non-specific
interaction of ReAsH with cellular protein thiols. After a washing step with a higher
concentration of EDT (100 ]iM), red ReAsH signal was visible within endosomes. A dif
fuse background of red signal within the cell body was also present. Examination of
the GFP fluorescence

showed a pattern of bright puncta combined with thin branching

and anastomosing tubules forming a reticular network concentrated near the nucleus.
This pattern is similar to that observed after transfection with wild-type HLA-A2-GFP,
although with decreased signal originating from the plasma membrane (compare fig
ure 2.3 with figure 2.5). When the images of GFP fluorescence and ReAsH signal were
overlaid, the areas of more intense ReAsH signal colocalized with GFP positive vesicles,
confirming that the presence of ReAsH signal from these vesicles was due to the presence
of the C4-tagged HLA-A2 molecules.

2.2.4

Dicysteine HLA-A2 variants are not loaded with dicysteine-containing
A2-binding peptides.

Initial trials of 'feeding' dicysteine containing peptide to HeLa cells transfected with
dicysteine containing HLA-A2 molecules led to high cellular background, and no ap
preciable signal. To bias the system toward the formation of peptide-MHC complexes
containing bipartite tetracysteine motifs, we relied on observations that in cells harbor
ing loss-of-function mutations in the transporter associated with antigen presentation
(TAP), expressed MHC molecules are retained in the endoplasmic reticulum, but the
addition of exogenous peptides can lead to peptide loading and stabilization of MHC
surface expression[88, 74]. Three such TAP- cell lines were available as kind gifts of
the Cresswell laboratory, RMA-S (mouse H.-2b), T2 (human HLA-A2+//+), and Bufi.280
(human, HLA-A2"/_, [89]). Both RMA-S and T2 are lymphocytic in origin, and thus are
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challenging targets in experiments using microscopy for the determination of subcellular
localization. Bufi28o, on the other hand, is a melanoma cell line (epithelial in origin) that
adopts a broad flat morphology preferable for microscopy. This cell line harbors a 2 bp
insertion mutation that inactivates HLA-A2 expression, but transfection with wild-type
HLA-A2 and TAP rescues the surface expression defect[89]. Thus we chose the Bufi28o
cell line to test whether the dicysteine containing peptides identified in database searches
could bind to the dicysteine containing HLA-A2 variants.
To begin, we first used flow cytometry to confirm that expression of HLA-A2 in
Bufi28o cells led to low levels of surface expression and was unstable. HeLa cells trans
fected with HLA-A2-GFP show two histogram peaks when stained with BB7.2-PE. A
high staining peak (characteristic of transfected cells) and a low staining peak (character
istic of untransfected cells). When compared to the levels of surface expression of wild-

Figure 2.6 (following page): Surface stabilization of dicysteine containing HLA-A2 variants
in cells lacking TAP. (a) HeLa cells transfected with wild-type HLA-A2-GFP express high
levels of stable surface HLA-A2 as detected by BB7.2-PE staining, (b) Bufi28o cells, when
transfected with wild-type HLA-A2-GFP show low levels of surface expression. For pan
els a and b, cells showing FSC/SSC profiles and PI negative staining (characteristic of
living cells) are included in this histogram. Expression of HLA-A2 on the surface of
Bufi28o cells can be stabilized by incubation for 4 hrs at 37°C with media supplemented
with 10% serum (c, blue histogram, gated GFP+) orio jiM. YLLCCNYKL, an HLA-A2
binding peptide (d, grey histogram, gated GFP+). Cells incubated in serum free media
(red histogram in c, blue shaded histogram in d, both gated GFP+) and GFP- untrans
fected cells (grey shaded histograms) are shown as controls, (e) Surface stabilization of
HLA-A2 by serum on Bufi.280 cells compared to the levels of surface expression in HeLa
cells. Surface expression of HLA-A2 is unstable, (f) After incubation in media supple
mented with serum overnight, HLA-A2-GFP expressing Bufi28o cells were incubated in
HBSS without serum for varying times, (g) Mean fluorescence intensity as a function of
time, (h) HeLa cells expressing HLA-A2 and incubated with or without serum for 4 hr
at 37°C show similar levels of surface HLA-A2. (i) A schema for the determination of
the surface stabilization of dicysteine containing HLA-A2 variants by dicysteine containing peptides. Bufi28o cells transfected with HLA-A2 variants are incubated overnight in
serum free media with or without YLLCCNYKL peptide before staining with BB7.2-PE to
measure the levels of surface HLA-A2. (j) Measurement of HLA-A2 surface stabilization
on Bufi28o cells by dicysteine containing peptide. In every case examined, the levels of
surface HLA-A2 were the same (R89/A93, K90/A93, K170/A174) or lower (Q179/A182)
in the presence of peptide (red histograms) than in its absence (blue histograms).
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type HLA-A2 when transfected into HeLa cells (fig. 2.6a), the same allele transfected
into Bufi28o cells showed lower expression levels (fig. 2.6b). This low level of expression
could be increased by incubating the cells in media containing serum, or in serum free
media supplemented with 10 pM YLLCCNYKL, a high-affinity HLA-A2 binding peptide
(fig. 2.6c and d). While incubation with peptide increases surface expression, the levels
are still low compared to the steady state level in HeLa cells (fig. 2.6e). Peptides stabilize
levels of surface expression transiently; removing the cells from media containing serum
results in a time dependent decrease in surface folded HLA-A2 (fig. 2.6f), with a half-life
of approximately 2.5 h (fig. 2.6g). By contrast, when HeLa cells expressing HLA-A2 are
incubated in the presence or absence of serum for 4 hr, the levels of surface HLA-A2 are
similar (fig. 2.6h). These results confirm that expression of HLA-A2 on the surface of
TAP-/~ cells is not long lived, but can be increased through the addition of exogenous
peptide, either in the form of serum, or in the form of specific HLA-A2 binding peptides,
such as YLLCCNYKL.
To test whether YLLCCNYKL stabilized dicysteine containing variants of HLA-A2,
I transfected Bufi 280 cells with plasmids encoding HLA-A2 incorporating dicysteine
residues at positions R89/A93, K90/A93, K170/A174 or Q179/A182. The cells were
then incubated in serum free media or in serum free media supplemented with 10 }iM
YLLCCNYKL. After overnight incubation at 37°C, the levels of surface HLA-A2 were
examined by flow cytometry (for schema see fig. 2.6i). As can be seen in figure 2.6j, the
levels of surface expression of HLA-A2 variants incorporating dicysteines at positions
R89/A93, K90/A93 or K170/A174 were similar regardless of the presence or absence of
the HLA-A2 binding peptide. For the HLA-A2 variant harboring cysteine residues at
positions Q179/A182, the addition of the peptide decreased surface expression. Taken
together, these results indicate that while the YLLCCNYKL peptide stabilizes the surface
display of wild-type HLA-A2, it fails to stabilize the surface display of any of the 2C
variants tested.
The absence of surface stabilization of HLA-A2 when Bufi28o cells were treated with
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2C containing peptide suggest that the peptide failed to form complexes with the HLAA2 heavy chain. These results make it unlikely that a bipartite tetracysteine motif is
formed by the close association of heavy chain and exogenously applied peptide, and
make it unlikely that the specific staining will be observed after treating these cells with
ReAsH. Indeed, in other experiments, the addition of dicysteine containing peptides sub
stantially increased the cellular background after ReAsH staining, making the likelihood
of observing specific peptide-MHC complexes using this method very small.

2.3 Discussion
Dicysteine containing HLA-A2 side chains were expressed in TAP-/~ cells, but their
surface levels were very low relative to wild-type HLA-A2, even though the surface ex
pression level of these alleles were comparable in TAP+/+ (HeLa) cells. These data are
in line with findings that TAP plays a role in the folding of MHC-i heavy chains[38], not
just peptide loading, and supports the hypothesis that the addition of cysteines to the
heavy chain represents a challenge to the folding of MHC-i that is made more difficult by
the absence of TAP. The MHC-i loading machinery consists of the MHC-i heavy chain,
^-microglobulin, TAP, tapasin, ERp57, and the chaperones and calreticulin. Exclusion
of ERp57, an ER resident protein disulfide isomerase, from the MHC-i loading complex
through the expression of a tapasin mutant[9o] or ERp57 deletion[78], results in aggre
gate formation. These aggregates contain tapasin, unfolded MHC-i, as well as other
proteins. One current model is that tapasin forms a bridge connecting TAP and MHC-i
with ERp57 and calreticulin[9i]. In this model, ERp57, MHC-i and tapasin should as
sociate independently of TAP. In fact, in vitro experiments have shown that tapasin and
ERp57 are the minimal functional unit of the peptide loading complex[77]. Thus, why
the deficiency of TAP should lead to a selective decrease in the surface expression of
dicysteine containing HLA-A2 molecules, even in the presence of exogenously added
HLA-A2 binding peptides, remains a mystery.
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When DNA encoding dicysteine containing HLA-A2 molecules was transfected into
TAP+/+ HeLa cells, the proteins were detected on the cell surface, but whether these
molecules were loaded with peptide was not tested. I found that the addition dicysteine
containining HLA-A2 binding peptides did not stabilize dicysteine containing HLA-A2
heavy chains on the surface of TAP-/~ cells, even though these same sequences did
stabilize the surface expression of wild-type HLA-A2. One possibility for this difference
is that the combination of mutations within dicysteine containing HLA-A2 heavy chains
and dicysteine containing HLA-A2 binding peptides prevent association and stable fold
ing of the complex.
Alternatively, these data may point to an additional role for TAP in the MHC-i pep
tide loading complex. Unfolded MHC-i binds to calreticulin and tapasin for incorpo
ration into the loading complex[91]. Even though MHC-i does not bind to TAP in the
absence of tapasin[9x], it remains unstudied whether efficient recruitment of MHC-x into
a complex with ERp57 and tapasin is affected by the absence of TAP.
The hypothesis that MHC-x recruitment into the peptide loading complex is slower
in the absence of TAP would explain the findings above. In the case of the wild-type
allele, such efficient recruitment may not be necessary, because the protein may fold
with an efficiency high enough to maintain reasonable expression levels. On the other
hand, in the case where cysteine residues are added to the heavy chain, the absence of
swift recruitment to the protein disulfide isomerase ERp57 may lead to a kinetic trap of
improperly folded HLA-A2. Rapid recruitment to the tapasin-ERp57 loading machinery
in the presence of TAP may occur before such misfolding occurs, in the absence of TAP,
the expression of HLA-A2 with additional cysteines thus may be severely hindered.
While this study was ultimately unsuccessful in defining the MHC-x cross presen
tation pathway, it did provide several important lessons. These lessons take two forms:
principles for choosing target pathways likely to be successfully interrogated by bipartite
tetracysteine display, and required features of strategies interrogating cross presentation.
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2.3.1

Future Directions I: Strategies for interrogating cross presentation

As illustrated earlier, cross presentation represents a number of particularly vexing challeges. The activation of T cells may occur with very few peptide-MHC complexes (<3
for CD8+ T cell killing [92, 93]), so the detection must be exquisitely sensitive. These
peptide-MHC complexes may be distributed across multiple areas of the cell, requireing
the ability to detect single molecules. Indeed it is now appreciated that T cells could
recognize single molecules long before microscopes could do so[94]. Thus most of the
productive approaches to detecting the cellular pathways have used T cell responses
as a functional read-out of whether pathways for cross-presentation remain intact af
ter experimental purterbation. And specific theories regarding the cellular trafficking of
membrane and endosomal contents are tested as they arise.
Three studies[95, 96, 97] suggested that the fusion of the endoplasmic reticulum (ER)
with maturing phagosomes could explain the cross presentation of antigens derived from
intact protein. The theory, now wide-spread, is that ER retrotranslocation machinery
would pull denatured proteins from the ER to the cytoplasm. A functional role for
the ER associated degradation (ERAD) machinery in cross-presentation was provided
soon after the initial studies [98, 99], however the notion that the membrane that fused
with nascent phagosomes originated from what was canonically considered the ER was
challenged[ioo]. Thus a picture in which the ERAD machinery may be functional out
side the ER has emerged, or that phagosomes may fuse with ER-like vesicles containing
enzymes thought to be resident only in the ER. Recent studies have suggested that the
core component of the ERAD machinery, P97, can be recruited to early endosomes by
poly-ubiquitinated mannose receptor[ioi]. Functional studies arresting the maturation
of early or late endosomes may shed light on vesicular pathways required for cross pre
sentation.
Are exogenously derived peptides segregated from endogenous antigen during crosspresentation? At least one group[96] has argued that proteasomes are associated with
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the cytoplasmic side of phagosomes and the proteolysis products may be imported back
into phagosomes from which they were previously exported. This would provide a way
to segregate two classes of MHC-i, one that was loaded in the phagosome, and another
that was loaded in the ER. Presumably the antigenic origins of these two populations
are distinct, and the cell could regulate their trafficking differently. No data exists to
support this model. However, research has shown that some MHC-x does pass out of
the ER into phagosomes where it is loaded and traffics to the cell surface without passing
through the golgi (identified through endoglucosidase H sensitivity)^]. Thus at least
two populations of peptide loaded class I proteins exist: those that have passed through
the golgi, and those that have not.
All of the pathways enumerated in figure 2.1 are likely to be operable at different
times and in different cells. Nevertheless, the mechanism of cross-presentation of anti
gens derived from endocytosed proteins is perhaps the most interesting from a cell bio
logical standpoint. Despite its importance from the standpoint of vaccine development
and understanding basic cellular processes, no available techniques are truly well suited
to answer the questions presented in the beginning of this chapter.
With improvements in live cell microscopy, photodynamic /photoactivation approaches
may be able to determine which population of MHC heavy chains carry cross presented
peptides. In an alternative approach, one could imagine purifying high-mannose heavy
chain and examining the mass spectra of the eluted peptides. This may provide one
way to determine whether cross-presented antigen is selectively loaded on phagosomal
MHC-i rather than in the ER.

2.3.2

Future Directions II: Targets of choice for bipartite tetracysteine display

The experiments outlined here were targeted not only at gaining a better understanding
of antigen cross-presentation, but also at gaining a better understanding of methods and
criteria for the use of bipartite tetracysteine display. One principle that has emerged
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from in vitro protein labeling studies is the need for site flexibility in selecting protein
regions in which to incorporate bipartite tetracysteine motifs[io2]. The factors presenting
challenges during this work have illustrated guidelines for future choices of cellular
systems and pathways likely to be successfully interrogated by this technique.
At least four priciples for success have emerged. Systems likely to be successfully
interrogated by bipartite tetracysteine display have (i) high levels of expression of a ho
mogenous target, this leads to high concentrations of tetracysteine targets for labeling. (2)
It is preferable that biological manipulations can leads to the presence versus the absence
of the formation of the bipartite tetracysteine motif, this removes the need to distinguish
between 'levels' of labeling, a distinction that requires a dynamic range roughly 5-10
times larger than that required to determine a binary (present vs absent) response[xo3].
(3) The presence if the tetracysteine motif near the cell surface allows the use of total
internal reflection (TIR) fluorescence microscopy (TIR-FM), a technique that selectively
excites the ~ioo nm of the cell closest to the water-glass interface[i04], and can eliminate
much the cytoplasmic background seen after ReAsH staining. (4) The tetracysteine motif
should be located in the cytoplasm, to remove the need for acute reduction of oxidized
thiols.
In retrospect, the bipartite strategy outlined above for the detection of crosspresented
MHC-peptide complexes incorporated none of these priciples. With advances in micro
scopic techniques and approaches, advanced image process, new profluorescent fluorophores, or a better understanding of the 'optimal' bipartite tetracysteine motif, some
or all of these restrictions could be relaxed in the future.
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2.4

Experimental Methods

2.4.1

In silico mutagenesis and structural analysis of MHC-i and ReAsHFLN CCPGCCMEP

To determine the intra-atomic distances likely to for a suitable tetracysteine motif for the
binding of ReAsH, the PDB file containing the lowest energy conformer from the NMRdetermined structure of ReAsH complexed to the peptide FLNCCPGCCMEP was loaded
into MacPyMol(www.pymol.org). The PDB coordinates were provided by Roger Tsien.
The distances between atoms were determined using the 'Measurement' tool in PyMol.
The distances between sulfur atoms or ^-carbons (cysteine side chains) were measured
and are shown in figure 2.2.
To determine possible sites of mutagenesis on the HLA-A2 heavy chain, the PDB file
lJHT [76] was examined. This structure contains HLA-A2 bound to the antigenic peptide
ALGIGILT. Surface residues exposed residues (surface exposure > 2.5A2) were identified
using the findSurfaceResidues (script available at http: //www.pymolwiki .org/
index.php/Category:Script_Library). In this structure the antigenic residues in

IGIL (amino-acids 4-7) are surface exposed. Residue 2 (L) shows a surface exposure of >
o

2.5 A, however, the leucine side chain is pointing into the peptide binding groove, while
O

residue 3 (G) shows a surface exposure of < 2.5 A, but the backbone atoms are unburied.
The assignment of this residue as buried may be because the side chain of residue 4 (I)
is pointing out from the peptide binding grove, covering this amino acid. Thus residues
3-7 were selected as possible sites for cysteine incorporation. Next, residues containing
atoms within 8A of any atom within peptide residues 3-7 were selected. Surface exposed
residues within this selection were chosen as an initial set from which to design possible
cysteine incorporation sites. These residues are listed in table 2.1. Modeling the distances
from the a—carbon residues revealed that some combinations of these side chains existed
in preferable geometry, and these were selected for mutagenesis.
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Residue
R89*
K90
A93
H94
V97
R98
T100
T146
T147
K170
W171
A174
H175
V175
Ai77
Qi79
A182
Y183

Reason for Inclusion/Exclusion
Included
Included
Included
Points away fom binding groove
Included
Points away fom binding groove
Included
Too far from peptide
Too far from peptide
Included
Side chain buried
Included
Points away fom binding groove
Kink in a-helix, no obvious pair
Included
Included
Included
Included

Could Pair With
A93
A93
R89, K90
T100
V97

A174
K170

Qi79
A177, A182
Q179
Q179

Table 2.1: Residues of HLA-A2 selected for installation of cysteines. Residue R89 was
selected by visual inspection, the other residues were selected by the criteria that they
contain > 2.5 A of solvent exposed surface, and contained atoms <8 A from from atoms
contained within the residues 3-7 of the antigenic peptide.

30

2.4-2

Generation of dicysteine containing HLA-A2-GFP variants

Mutations within the helical segments of HLA-A2 adjacent to the peptide binding groove
were installed using QuikChange mutagenesis. Primer design was accomplished using
the QuikChange primer design program on the Stratagene website. Primer sequences
are listed in table 2.2. A plasmid containing the cDNA for HLA-A*020i was a kind gift
of Ira Mellman and Lelia Delmarre, and was used as a template for the mutagenesis
reactions.
To install an N-terminal tetracysteine motif, QuikChange mutagenesis was used to
instal an NgoMIV site within the coding region of HLA-A*020i, C-terminal to the signal
sequence. The installation of this restriction site did not alter the amino acid sequence
of the protein. Next, after desalting using G-25 microspin columns, oligos NC4-Tag
and NC4-Tag_R were annealed in T4 DNA ligase buffer. The annealed oligo pair and
the plasmid containing the inserted NgoMIV were both digested with the NgoMIV. The
plasmid was treated with antarctic phosphatase, and both the insert and plasmid were
purified using a PCR cleanup kit from Qiagen. The insert was then ligated into the vector
using T4 DNA ligase, and transformed into e.coli. Positive transformants were screened
by restriction digest and confirmed by DNA sequencing.

2.4.3

Immunofluorescence of HLA-A2-GFP and dicysteine containing vari
ants

HeLa cells were transfected using Fugene HD (Roche) according to the recommended
protocol. The following day, #1.5 round glass coverslips were coated with alcian blue
by submerging the coverslips in a solution of 1% (w/v) alcian blue in water. The so
lution (and coverslips) was boiled under close supervision using microwave heating for
20 seconds, after which the solution was left to cool at room temperature for 10 min.
After cooling, the alcian blue solution was recovered, and the coverslips washed exten
sively in deionized water. The coverslips were sterili2:ed by submersion in 75% ethanol
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Primer Name

Note

HLAA2R5
HLAA22F
HLAA23F
R89_A93
R89_A93_R
K9O-A93
K90_A93_R
Qi79_Ai82
Qi79_Ai82_R
Qi79_Yi83
Qi79 _Yi83_R

Reverse Seq
Forward Seq
Forward Seq
QuickChange

g72C

Add NgoMIV site

g72c_R
NC4-Tag
NC4-Tag_R

Sequence (5' - 3')
CAGCGTGGTGAGTCATATGCGTTT
AGAGGATGGAGCCGCGGG
CGCGGGGAGCCCCGCTTCAT
GAGTATTGGGACGGGGAGACATGCAAAGTGAAGTGCCACTCACAGA

//

TCTGTGAGTGGCACTTCACTTTGCATGTCTCCCCGTCCCAATACTC

//

GGGACGGGGAGACACGGTGCGTGAAGTGCCACTCACAGACTCACC

//

GGTGAGTCTGTGAGTGGCACTTCACGCACCGTGTCTCCCCGTCCC

//

GGCCCATGTGGCGGAGTGCTGGAGATGCTACCTGGAGGGCACG

//

n
//

it

CGTGCCCTCCAGGTAGCATCTCCAGCACTCCGCCACATGGGCC
CATGTGGCGGAGTGCTGGAGAGCCTGCCTGGAGGGCAC
GTGCCCTCCAGGCAGGCTCTCCAGCACTCCGCCACATG
CCAGACCTGGGCCGGCTCTCACTCC
GGAGTGAGAGCCGGCCCAGGTCTGG
CAGCGCCGGCTTTTTAAATTGCTGCCCCGGGTGCTGCATGGAACCGGGAAGTAGTGGAAGTAGTGCCGGCGAGC

//

GCTCGCCGGCACTACTTCCACTACTTCCCGGTTCCATGCAGCACCCGGGGCAGCAATTTAAAAAGCCGGCGCTG

Table 2.2: Oligonucleotides used in this study. All are listed 5'-3'. The 'R' indicates the oligonucleotide is the reverse-complement
of another entry with the same designation, or designed to sequence in the 3'-5' direction.

in water, and allowed to dry on a kimwipe in a cell culture hood. After drying the cov
erslips were placed in a 12 well tissue culture plate. Transfected HeLa cells were lifted
from their culture flask by treatment with trypsin, diluted in media, and approximately
50,000 transfected HeLa cells were added to each coverslip-containing well and allowed
to adhere overnight. The following day, cells were stained by incubation in FACS buffer
(Hanks Balanced Salt Solution, HBSS, Gibco Cat# 14025, with 0.5% (w/v) bovine servun
albumin added) containing a 1:500 dilution of BB72-PE for 1 hr. After labeling, cells
were washed extensively in labeling buffer, and then lightly fixed and nuclei labeled
by submersion in fixation buffer (4% paraformaldehyde in PBS) containing 300 nM 4',6diamidino-2-phenylindole (DAPI) for 5 min at RT, after which they were washed and
mounted on glass slides using GelMount (Biomeda) or FluoroGel (Electron Microscopy
Sciences). The slides were imaged using a 40X LD-NeoFluar objective on a Zeiss Axiovert
200M. Images for GFP, PE and DAPI fluorescence

were aquired using Zeiss filter sets 44,

43, and 49, respectively, on a MRm camera and analyzed using ImageJ.

2.4.4

Flow cytometric analysis of surface-expression of HLA-A2-GFP and di
cysteine containing variants

HeLa or Bufi28o growing in plastic tissue culture treated plates were transfected using
Lipofectamine2000 (Invitrogen) according to the manufacturers instructions. After grow
ing overnight, the cells were washed twice with PBS (without calcium or magnesium)
before lifting from the growth substrate by incubating at 37°C for 30 min in 2 mL PBS
supplemented with 1 mM each EDTA and EGTA. The cells were collected by centrifugation (500 x g, 7 min) and resuspended in FACS buffer. The cells were then placed
in a round bottom 96 well microtitre plate and labeled by incubation for 1 hr at 4°C in
150 jWL of FACS buffer containing a 1:500 dilution of BB7.2-PE. After labeling, the cells
were washed twice in FACS buffer, and resuspended in 500

FACS buffer containing

1 ^g/mL propidium iodide. The cells were maintained on ice until analysis by flow
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cytometry (FACSCalibur, BD). Histograms were constructed in Flowjo (TreeStar) after
excluding dead cells by gating on forward and side scatter, and selecting a propidium
iodide negative population. Channel compensations were conducted at the time of ac
quisition using control samples containing only a single fluorophore. In some cases, the
mean fluorescence intensity (MFI) is shown. This value is the geometric mean of at least
10,000 cells falling within live gates defined by forward scatter, side scatter, and PI fluo
rescence. In some cases, these values are gated on GFP+ cells, in which case the number
of cells analyzed before GFP gating was >10,000.

2.4.5

ReAsH staining of tetracysteine-tagged HLA-A2-GFP

HeLa cells grown on glass bottom dishes (MatTek) were transfected with C4-HLA-A2GFP using Fugene according to the manufacturer's instructions. After overnight expres
sion, the cells were washed twice with HBSS and incubated for 20 min at 37°C in 200 ^L
ReAsH labeling solution containing 1

ReAsH, 10 }iM EDT, 10 mM tributylphosphine,

1 mM CaCl2 and 1 mM MgCl2 in PBS (Gibco Cat# 14190). The cells were then washed
twice with 2mL PBS and incubated for 20 min at 37°C in 2 mL ReAsH wash solution con
taining 100 jiM EDT, 10 mM tributylphosphine, 1 mM CaCh and 1 mM MgC/2 in PBS.
The cells were washed twice with PBS and incubated for 10 min at room temperature
in 2mL HBSS containing 300 nM Hoescht 33342 before imaging. Images were acquired
using a 40X LD-NeoFluar objective on a Zeiss Axiovert 200M. Images for GFP, ReAsH
and Hoescht fluorescence were aquired using Zeiss filter sets 44, 43, and 49, respectively,
on a MRm camera and analyzed using ImageJ. To better visualize ReAsH labeling of
endosomes, some images were enhanced using the 'unsharp mask' filter, in which the
image is blurred and the blurred image subtracted from the parent image. This has the
effect of enhancing bright spots and decreasing background.
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2.4.6

Surface stabilization of dicysteine containing HLA-A2 variants by serum

Bufi 280 or HeLa cells transfected with HLA-A2-GFP or cysteine containing variants were
grown in RPMI-1640 + 10% FBS overnight. The following day, the cells were washed
twice with 2 mL HBSS before incubating (at 37°C) in either HBSS, HBSS + 10% FBS,
RPMI-1640 (serum free media) or RPMI-1640 + 10% FBS (media + serum), for the indi
cated length of time. The cells were them washed twice with 2 mL PBS and detached
from the plate using 2 mL PBS supplemented with imM each EDTA and EGTA. The
cells were diluted into FACS buffer, collected by centrifugation, and stained for surface
HLA-A2 as described in §2.4.4.
To determine the rate of disappearance of surface HLA-A2, Buf 1280 cells grown in
6 well tissue culture plates were transfected with HLA-A2-GFP and allowed to express
the protein overnight in RPMI-1640 + 10% FBS. At selected times the following day, indi
vidual wells were washed twice with 2mL HBSS, and the incubated further for varying
amounts of time in HBSS without serum. Following incubation the cells were detached
from the plate using 2 mL PBS supplemented with imM each EDTA and EGTA. The cells
were diluted into FACS buffer, collected by centrifugation (500 x g, 7 min) and stained
for surface HLA-A2 as described above.

2.4.7

Surface stabilization of dicysteine containing HLA-A2 variants by pep
tide

Bufi 280 cells transfected with HLA-A2-GFP or cysteine containing variants were grown
in RPMI-1640 + 10% FBS overnight. The following day, the cells were washed twice with
2 mL HBSS before incubating for at least 8 hr in either HBSS or HBSS supplemented with
10 jiM YLLCCNYKL. The cells were them washed twice with 2 mL PBS and detached
from the plate using 2 mL PBS supplemented with imM each EDTA and EGTA. The
cells were diluted into FACS buffer, collected by centrifugation, and stained for surface
HLA-A2 as described in §2.4.4.
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Chapter 3

Discrete Arginine Topologies Direct
Cytosolic Access
3.1 Background
Protein drugs-also known as biologicals-represent a rapidly expanding class of ther
apeutic molecules[i05]. However, their actions are limited primarily to extracellular
targets[io6,

107]

because the size and composition of most polypeptides and proteins

do not facilitate their uptake into mammalian cells[io8]. It has been known for over
40

years that addition of cationic charges to a peptide or protein can aid transport into

cells[i09, 110, in], and many reports have demonstrated the utility of appending basic
sequences derived from the HIV Trans-Activator of Transcription (Tat), D. melanogaster
Antennapedia, or simply polyarginine (for example, Arg8) to peptides to increase their
cytoplasmic access[ii2,

113, 114, 115,

116, 1x7]. Certain highly positively charged pro

teins also possess cell penetrating properties[n8,

X19],

but it remains unknown how

one can leverage these examples to control the precise entry pathway or enhance the
determinants for uptake.
Three contrasting mechanisms for cytosolic entry of cationic proteins and polypep
tides have been proposed. The first (ion pair-guided passive diffusion) posits that guani-
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dinium side chains on the polypeptide form hydrogen bonds with cell surface phospho
lipids creating neutral ion pairs that passively diffuse across the plasma membrane[i20,
121]. The second model (endosomal release), asserts that endocytosis is a major portal
through which cationic proteins and polypeptides enter the cell[io6, 122, 123], followed
by endosomal release. Previous investigations have attempted to distinguish between
these two models by blocking endocytosis, via thermal[ii5], pharmacologic[n6,123], or
genetic means[n6, 124]. The interpretation of these experiments is complicated, how
ever, by differences in protein/polypeptide concentration and analytical method. Re
cently, a third mechanism for cytosolic entry was described: at concentrations > 10
pM incubation of living cells with cationic proteins/polypeptides leads to the formation
of nucleation zones[i25] that transiently disrupt membranes[i26]. This results in the
spontaneous release of peptide into the cytosol. In the presence of drugs that inhibit
endocytosis, incubation of cells at lower concentrations (< 5 pM) of peptide prevents cy
toplasmic access[n6], implying that, at low concentrations, the molecules studied cannot
diffuse through the plasma membrane. The many studies using microscopy to examine
cells fixed by treatment with formaldehyde or methanol[i27] must be reevaluated in light
of evidence that the fixation process releases fluorescently labeled peptides from endo
somes, an artifact not observed during microscopic examination of living cells[i27]. Fi
nally, the high intensity light used for illumination during microscopy can itself facilitate
the redistribution of fluorescently labeled peptides from endosomes to cytoplasm[i28].
Thus, whether, when, and how these cationic molecules escape endocytic vesicles to
access the cytosol remain unanswered questions.
Attempts to identify and improve upon the structural determinants of cell perme
ability are complicated by the above experimental details as well as the fact that neither
Tat nor Arg8 possesses a defined fold. Miniature proteins are a family of small (36-aa),
well-folded polypeptides that adopt a characteristic hairpin fold consisting of axially
packed a- and PPII helices[i29, 130]. Miniature proteins identified through both rational
design[i5, 17] and molecular evolutional, 132, 19] can modulate protein function by
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inhibiting protein interactions!^, 18]; both loss of function and gain of function activ
ities have been observed[i32, 19, 18]. We reported previously that minimally cationic
miniature proteins containing between 2 and 6 arginine residues embedded within the
a- or PPII helix were taken up by mammalian cells in culture more efficiently than Tat
or Arg8[i33, 134]. Now, we turn to investigate whether miniature proteins containing
arginine reach the cytoplasm.

3.2 Results
To learn more about the structural determinants of cytoplasmic access, we designed a set
of miniature proteins that differed in the number and density of a-helical arginine side
chains, and tracked their passage into the cell. Using low concentrations (1 jiM) of vari
ants conjugated to a fluorophore, we found that a minimum of 4 a-helical arginines was
required for uptake, and cell uptake was enhanced when the arginines were clustered
on the same a-helix face. Next, a novel and rapid assay for evaluating cytoplasmic ac
cess revealed that of four cationic miniature proteins taken up by cells, only one reaches
the cytosol. This miniature protein, which we termed 5.3, possesses a distinct array of
five dispersed a-helical arginines on three helical faces. Direct comparisons show that
after treatment for as little as 30 min, the cytoplasmic concentration of 5.3 reaches lev
els as high or higher than that achieved by Tat or Arg8. Experiments monitoring the
degradation of proteins that reach the cytosol show that 5.3 displays remarkable stability
compared to Tat or Arg8, cationic peptides that do not posses a stable fold. These exper
iments demonstrate that discrete arginine arrangements embedded within a well-folded
miniature protein can direct cytosolic access.

3.2.1

Miniature Protein Design

To examine the effect of charge density and orientation on cell uptake, I prepared a va
riety of miniature proteins, using avian pancreatic peptide (aPP, structure shown in Fig.
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3-ia) as a scaffold[i30,129], that contained variety in the number and positioning of pos
itively charged arginine substitutions. The stability of the aPP fold[i35] allows variation
to be introduced into solvent exposed residues without compromising structure. The
eight miniature proteins, as well as the wild-type sequence, together contained between
one and six arginine residues at various positions on the solvent-exposed a-helical sur
face of the hairpin fold (Fig. 3.1b). These molecules also contained two arginines near
the C-terminus (Fig. 3.1c).
To ensure the arginine residues were displayed as intended, circular dichroism (CD)
spectra of the miniature protein variants were obtained (Fig. 3.2). Seven of these cationic
miniature proteins were characterized by CD spectra at 37°C that were virtually indistin
guishable from that of the parent molecule lacking additional arginines, aPP (Fig. 3.2a).
The CD spectra of six were temperature-dependent with cooperative transitions between
49 and 6y°C (Fig. 3.2b,c) suggesting that they each retained a stable and characteris
tic hairpin fold[i3o]. Miniature protein 6.3, containing the greatest number of arginine
substitutions (6), showed reduced ellipticity at 222 nm and 208 rim (Fig. 3.2a), along
with a reduced Tm of 33°C (Fig. 3.2b,c); 6.3 was not studied further. For the remain
ing molecules, these data suggest that arginine substitution does not significantly alter
miniature protein secondary structure, and that Fig. 3.1b accurately represents the argi
nine side chain arrangement in miniature proteins 2.1, 2.2, 3.2, 4.2, 4.3, 5.2, and 5.3.

3.2.2

Cell Uptake

Initially we used flow cytometry to assess the influence of arginine number and orienta
tion on miniature protein uptake. In this technique cells are passed through a capillary
into a detection chamber illuminated by one or several lasers. Appropriately placed
photodetectors fitted with bandpass filters detect fluorescent signals. This allows the
amount of fluorescence associated with individual cells to be accurately and rapidly de
termined. In preliminary studies, we evaluated molecules labeled with fluorescein on
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Figure 3.1: Description of miniature protein structures and variation in arginine dis
play. (a) The structure of avian pancreatic polypeptide (PDB:iPPT) contains both a- and
polyproline-type helices, which are arranged in a hairpin. The interface is formed via
hydrophobic packing. The focus of this study was on determinants that could be placed
on the a-helix. (b) A.plot of the relationship between #Rtotni (the number of a-helical
arginine residues) and #Rf0Ces (the number of a-helical faces on which these arginines
are displayed) for each aPP variant. The location of each a-helical arginine residue is
represented by a blue circle on the helical wheel, (c) Amino acid sequences of peptides
shown in b. [This data assembled with Betsy Smith.]
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their C-termini (as denoted with superscript F). In our initial studies, we included a
trypsin wash just before analysis via flow cytometry. Treatment of HeLa cells with 5
aPPF, 2.1F, 2.2F, or 3.2F resulted in only small increases (< 3 fold) in cell fluorescence,
while treatment with 4.2F, 4.3F, 5.2F, or 5.3F resulted in increases in cell fluorescence
between 7 and 40 fold (Fig. 3.3a). We therefore chose to focus on miniature proteins
showing significant uptake.
To ensure that increased uptake was a property of peptide sequence and not of fluorophore location or identity, we confirmed these results by synthesizing analogs labeled
instead on their N-termini with tetraethyl rhodamine sulfate (denoted with superscript
R), a dye with several desirable properties including resistance to photobleaching and
an emission spectrum unaffected by pH changes and far from the autofluorescence
spectrum of cells[57]. As found for miniature proteins labeled with fluorescein,

rho

damine labeled miniature proteins containing four or five a-helical arginines were taken
up efficiently (Fig. 3.3b). Comparison of the relative fluorescence signal of cells treated
with peptides sharing the same sequence but labeled with different fluorophores reveals
a striking similarity, suggesting uptake is largely influence by the nature of the pep
tide, and not purely a characteristic of the fluorophore tag. We found that incubating
HeLa cells for longer time periods increased the fluorescence signal associated with cells
(Fig.. 3.3c), suggesting that peptides were being internalized in an ongoing, rather than
stochastic, process. Comparison of the fluorescent signal after 90 min vs 30 min reveals
that the rate of uptake is highest for miniature proteins containing clustered arginines
(4.2s and 5.2s) whose fluorescence intensities increase by 160% and 281% during this
time period, and is lower for TatR and Arg8R.
Importantly, flow cytometry places no restrictions on where a fluorescent signal origi
nates. Fluorescent molecules on the cell's surface, within the cytoplasm, or within intra
cellular vesicles all contribute to the total cellular fluorescence. To distinguish molecules
within cells, from those that remain on the cell's surface, previous researchers have at
tempted to decrease surface binding through lowering pH[i36, 137], adding competing
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Figure 3.2: Circular dichroism (CD) of miniature proteins used in this study, (a) Wave
length dependent CD spectra of peptides (25 ^M) in PBS at 37°C. (b) Temperature de
pendent ellipticity at 222 nm of peptides shown in a. (c) Calculated Tm of thermal melts
shown in b. [This data collected by Betsy Smith.]
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Figure 3.3: Cell uptake of cationic miniature proteins, (a) A plot of mean cellular fluorescence at 530 nm of HeLa cells treated with
fluorescently tagged miniature proteins (5 [iM, 30 min). (b) Comparison of the relative uptake of fluorescein and rhodamine labeled
miniature proteins sharing the same sequence. HeLa cell treated as in a, or with 1 ]iM rhodamine labeled miniature proteins for
30 min at 37°C. The mean fluorescence intensity (MFI) is normalized to the value for aPP. (c) Time dependent internalization of
cationic miniature proteins. HeLa cells treated with 1 fiM rhodamine labeled miniature proteins at 37°C for 30, or 90 min or treated
at 4°C ('0 min') before analysis, (d) Cellular fluorescence after treatment with 1 }iM rhodamine labeled miniature proteins in the
absence of endocytosis and removal by trypsin treatment. HeLa cells were treated for 30 min at 4°C were then treated with trypsin
(0.05%, 10 min, 37°C) or PBS before washing and analysis by flow cytometry, (e) Fraction of cell-associated fluorescence (d, black
bars) remaining after trypsin treatment (d, red bars), (f) Internalization efficiency of rhodamine labeled miniature proteins. [The
data in part a was collected by Betsy Smith]

binding substrate such as heparan sulfate[i38], or by degrading surface-bound protein
with trypsin[i38,127]. I therefore verified that trypsin treatment removed miniature pro
teins that were bound to the cell surface. Membrane traffic was arrested by incubating
cells at 4°C[i39, 140] for 15 min prior to and during a 30 min treatment with 1 pM 4.2s,
4-3R, 5-2r, 5-3R, TatR, Arg8R or aPPR as a negative control. After incubation, cells were
washed three times with PBS and incubated with trypsin (0.05% at 37°C for 15 min) or
PBS (as a control) before analysis by flow cytometry (Fig. 3.3d). Cationic miniature pro
teins 4-2R, 4-3r, 5.2R and 5.3s bound to cells between 2.7-fold and 35-fold more than aPPR
and in some cases (5.2s and 5.3s) to an extent comparable to TatR and Arg8R. For all
peptides, trypsin treatment decreased the fluorescent signal between 77-89% (Fig. 3-3e).
Because peptides and proteins that enter the cell are inaccessible to trypsin added to the
culture media[ii3], these data confirm that at 4°C, incubation of cells with 1 pM cationic
miniature protein leads to little if any cell uptake, and confirms that the vast majority
of material bound to the cell surface is degraded and/or effectively removed by trypsin
treatment.
Our finding that incubating cells in the cold substantially decreases the amount of
internalized fluorescence signal indicates that at 4°C neither cationic miniature proteins
nor Tat or Arg8 can enter the cell by diffusing through the plasma membrane. Two hy
potheses could explain this result. First, at 4°C the lipid character of the membrane may
be altered is such a way as to become less permeable to the peptides studied. Alterna
tively, the internalization of membrane is required for cell uptake, a process arrested at
4°C. These theories are not mutually exclusive. Nevertheless, this finding also provided
an opportunity to compare the efficiency of internalization, defined herein as the amount
of peptide internalized relative to that bound to the cell surface. In the absence of endocytosis (4°C), the amount of surface bound peptide was quantified using flow cytometric
analysis of cells that had been treated with 1 pM 4.2R, 4.3s, 5.2R, 5.3s, TatR, Arg8R or
aPPR, but not with trypsin(Fig. 3.3d). Values obtained after incubating cells at either 4°C
or 37°C (Fig. 3.3c) were normalized to this value. As can be seen in figure 3.3^ aPPR
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and 4-2R are internalized inefficiently, showing fluorescence values after 30 min roughly
equal to the amount originally bound to their surface. By contrast, 4-3R, 5-2R and 5.3**
are each internalized efficiently, incorporating more than 4 times the amount of peptide
originally bound to their surface. TatR and Arg8R show intermediate values, revealing
that the display of arginine side chains on cationic miniature proteins can be engineered
to induce highly efficient uptake by cultured cells.
These data show that cell uptake depends on arginine density and number; miniature
proteins containing four arginine residues clustered on two helical faces were taken up
to a greater extent than those containing four arginines on three helical faces (Fig. 3.3a,b).
Molecules containing five a-helical arginines were taken up to a similar extent irrespec
tive of density, revealing that among these molecules the impact of arginine arrangement
was smaller. Consistent with our previous work[i4i], the cationic miniature proteins
5.2R and 5.3R are taken up to a greater extent and with higher efficiency than TatR and
Arg8R, despite the fact that they possess twice the mass and fewer (7 rather than 8)
positive charges.

3.2.3

Cationic miniature proteins do not cause plasma membrane disruption.

Three limiting models have been invoked to explain the trafficking of cationic peptides
and proteins across the plasma membrane. The first posits that high local concentrations
of positively charged peptides cause membrane disruption[i25]. This is followed by
sudden release of peptide into the cell and triggers a membrane repair response[126].
A second model invokes ion-pair guided passive membrane diffusion[i2i, 120]. The
final model invokes endocytosis followed by endosomal release (vide infra). Membrane
disruption can alter cell physiology leading the leakage of cytoplasmic contents and cell
death[i42]. Therefore, we first confirmed that the integrity of the cell membrane is not
disrupted in the presence of 1 jjM cationic miniature protein.
To confirm that cationic miniature proteins do not cause membrane disruption, we
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Figure 3.4: Absence of membrane permeabilization after treatment with Dex-labeled
cationic miniature proteins. HeLa cells were incubated with 1 jiM of the indicated dexamethasone labeled miniature protein or peptide in the presence of 200 nM Syto Orange
(a cell permeable dye) and 200 nM Sytox Blue, a dye that is not cell permeable but
binds to nuclear DNA when cell membranes are disrupted. Saponin (10 ytg/mL) a deter
gent that permeabilizes mammalian cell membranes was used as a positive control, (a)
Schema showing experimental design; cells with intact membranes exclude Sytox blue
and are red only, cells with permeabilized membranes are red and blue, (b) Images of
cells treated as described in a with the indicated peptides. Very few show blue signal in
the nucleus, indicating intact cell membranes.
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treated HeLa cells with peptides in the presence of two dyes, one that is cell permeable
(Syto Orange), and one that is not (Sytox Blue). In the absence of membrane disruption,
cell bodies are labeled with the permeable dye and exhibit red fluorescence. No blue
fluorescence is observed from cells with intact membranes, however membrane disrup
tion allows for a high affinity interaction between Sytox Blue and DNA leading to bright
fluorescence within the nucleus (see Fig. 3.4a). As can be seen in figure 3.4b, HeLa
cells treated in media, indicated as (-) CTRL, show only red fluorescence, but after treat
ment with a saponin, a detergent capable of permeabilizing mammalian cell membranes,
bright blue fluorescence becomes visible within the nucleus. To test whether treatment
with IJAM cationic miniature proteins would lead to similar membrane compromise, we
treated HeLa cells with miniature proteins or peptides as indicated under analogous
conditions in the presence of Sytox Blue and Syto Orange for 30 min at 37°C. As can be
seen in figure 3.4b, very few cells show blue fluorescent nuclei, indicating that dexamethasone labeled cationic miniature proteins do not lead to membrane disruption. This
result suggests that at low concentrations and under these condition, neither cationic
miniature proteins nor Tat or Arg8 enter cells through this mechanism.

3.2.4

Cationic Miniature Proteins Reach The Cytoplasm

In many cases, cationic proteins/polypeptides showing cellular uptake by flow cytom
etry remain trapped in endosomes and fail to reach the cytosol[i28]. Previous work
has shown that the cytosolic localization of a peptide- or peptoid-dexamethasone (Dex)
conjugate can be detected using a glucocortocoid receptor-driven luciferase assay[143].
Interaction of a Dex-labeled peptide or peptoid with the ligand-binding domain of the
glucocorticoid receptor (GR) in the cytosol induces transcription of luciferase that is de
tectable in cell lysates 40-48 hours later. We sought to evaluate cytosolic localization on a
more rapid time scale, and took inspiration from reports that dexamethasone treatment
of cells in culture led to rapid (15 min) translocation of a GR-green fluorescent protein
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fusion (GR-GFP) from the cytosol to the nucleus[i44]. If this rapid translocation was also
observed in the presence of peptide-dexamethasone conjugates, then live cell microscopy
could provide a rapid assay for cytosolic localization in living cells.
To validate this approach, HeLa cells were transfected for 12 - 18 h with the gene
encoding GR-GFP, and then incubated for 30 min with between o and 10 pM dexamethasone (Fig. 3.5a). When dexamethasone was absent from the incubation media, these cells
exhibited GFP signal throughout the cytoplasm and the nucleus (Fig. 3-5e). Addition of
dexamethasone to a final concentrations between 3 nM and xo

led to a concentration-

dependent decrease in the cytosolic GFP signal and a concomitant increase in the nuclear
GFP signal (Fig. 3.5a). We quantified these changes using the automated image process
ing package CellProfiler[i45] (Fig. 3.5b,c) to measure the GFP signal in the nucleus as
well a 2 Jim (40 pixel) region surrounding region of the cytosol. I report the ratio of
the median GFP intensity in the nucleus and the surrounding region as a 'translocation
ratio'1 (TR, Fig. 3.5c). TR values near 1 indicate equivalent intensity between the nu
cleus and the surrounding region. Treatment of HeLa cells with 1

dexamethasone

for 30 min resulted in an increase in the translocation ratio from 1.07 ± 0.02 to 3.93 ± 0.14
(p = 1.92 x 10~22, vs untreated cells, two-tailed t-test), roughly 90.5% of value achieved
with a 10-fold higher concentration(Fig. 3 5d). We therefore chose this concentration for
subsequent studies.
When HeLa cells transfected with GR-GFP were treated for 30 min with 1 jiM aPF Dex ,
virtually no change in GR-GFP localization (Fig. 3.5c) or the calculated translocation
ratio (1.41 ± 0.09, vs 1.25 ± 0.04, p = 0.1473, two-tailed t-test, see also Fig 3.6b) was
observed. Among HeLa cells that were treated with media alone, the translocation ratio
was not significantly correlated with the level of expression of GR-GFP (R = 0.21, Fig.
3-5f). These data are consistent with the observation that aPPR fails to enter cells and
indicate that simply adding the dexamethasone label is not sufficient to confer upon an
'Others (e.g., Ding et al. (1998) J Biol Chem 273, 28897-28905) have reported similar values, which they
have named nuclear/cytoplasmic ratio, however because this term could be misconstrued to indicate the
relative concentration of GFP within these compartments, I have used the term translocation ratio instead.
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Figure 3.5: Dose dependent increase in translocation ratio following exposure to dex
amethasone. (a) Schematic of quantitation method. Cell images were examined using
CellProfiler to create a region containing the nucleus and a surrounding zone. The ratio
of the median intensity in these two regions is reported as the translocation ratio, (b)
Representative images of HeLa cells transfected with GR-GFP and treated with various
concentrations of dexamethasone as indicated. Red outlines show regions defined as nu
cleus and surround, (c) Translocation ratio observed plotted against the concentration of
dexamethasone added. Fitting these points to a hyperbolic curve yields an EC50 = 21.83
nM and a Hill coefficient of 0.97.
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otherwise cell impermeable peptide the ability to reach the cytoplasm[i43]. These data
also support the use of the translocation ratio as a useful measure of the relative ability
of Dex-labeled compounds to reach the cytoplasm of target cells.
I next evaluated the extent to which Dex-labeled miniature proteins, as well as Tat
and Arg8, induce the nuclear translocation of GR-GFP (Fig. 3.6). HeLa cells transfected
with GR-GFP were treated for 30 min with 1

4.z D e x , 4.3 Dex , ^.z D e x , 5.3°", Tat D e x ,

or Arg8Dex and the translocation ratio calculated. Treatment of HeLa cells with 5-3Dex
led to a large increase in translocation ratio (3.1 ± 0.1) both compared to an untreated
sample (-) (p = 2.68 x 10-48, ANOVA with Bonferroni post-test) or one treated with
appDex

(p _ J %

x

io~16). Treatment of HeLa cells with 4.2°", 4.3°", or 5.2°" led

to a small or absent increase in nuclear GFP signal, and translocation ratios (1.18 ± 0.04,
1.92 ± 0.10,1.77 ± 0.11 respectively) that were not significantly different from cells treated
with aPPDez. We also measured the nuclear accumulation of GR-GFP after treatment
with Arg8Dez or TatDex, which in both cases was increased over control samples treated
with aPPDex (Arg8Dex = 2.19 ± 0.13, p = 0.0053; TatDex = 2.85 ± 0.10, p = 2.54 x 10~9),
and comparable to cells treated with 5.3°**. These comparisons are illustrated in figure
3.6b.
The above data could be explained in several trivial ways. One explanation is that the
concentrations of Dex-labeled cationic miniature proteins and peptides used here could
lead to permeabilization of the cell membrane and direct access of the peptides studied
to the cytoplasm. However I previously verified that the plasma membrane retains the
ability to exclude the small organic dye Sytox Blue (Fig 3.4), making this possibility un
likely. Second, the peptide could be rapidly degraded, releasing free dexamethasone into
the cell and surrounding media, activating the GR and leading to its nuclear accumula
tion. Third, and perhaps less likely, by covalently linking dexamethasone to the cationic
miniature protein, a high affinity molecule is created, capable of activating the GR at
extremely low concentrations. I tested these final two possibilities directly by assaying
the proteolytic stability of the miniature protein backbone and by measuring the ability
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of dex-labeled cationic miniature proteins to compete with dexamethasone for the ligand
binding site of recombinantly expressed human glucocorticoid receptor in vitro.
To verify that the affinities of dexamethasone labeled cationic miniature proteins and
peptides for the human glucocorticoid receptor in vitro were similar to each other, we2
used a commercially available validated glucocorticoid screening assay, POLARSCREEN
GREEN®. In this assay, recombinant human glucocorticoid receptor is mixed with a fluo
rescently labeled steroid analog (FLUORMONE), that possesses a high affinity for the mineralocorticoid binding site. In the absence of competitor molecules, FLUORMONE binds to
GR and exhibits high polarization. As increasing concentration of competetor molecule
is added, FLUORMONE is displaced from the binding site. As its effective molecular size
is now reduced, the molecule tumbles in solution more quickly, and exhibits a polariza
tion value that is decreased. Fitting these data to a hyperbolic curve reveals the IC50,
the concentration of competetor molecule that results in a half-maximal decrease in the
polarization value of FLUORMONE.
Addition of cationic residues within the a-helix of the aPP scaffold resulted in a
trend of decreasing ability of Dex-labeled cationic miniature proteins to compete for the
GR binding site (Fig 3.7). The affinity of aPPDex for the GR (IC50 = 1.0 nM, 95% CI
= [0.6,1.7]) was similar to dexamethasone itself,

(JC50

= 0.85 nM, 95% CI = [0.5,1.4]),

whereas the affinity of 5.3°"' was lower (IC50 — 35.9 nM, 95% CI = [25.1,51.3]). Minia
ture proteins 4.2°", 4.3°", and peptides TatDex and Arg8De* gave intermediate val
ues (between 2.7 - 8.6 nM), all slightly poorer than unconjugated dexamethasone (see
Fig 3.70-h). Because the apparent affinity of 5.3°" is lower than the other molecules stud
ied in this panel, its increased ability to activate the glucocorticoid receptor in cells must
invoke either a non-competetive mechanism or a higher effective concentration within
the cytoplasm, or both.
2This

work was completed with the assistance of Justin Holub
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3.2.5

Cell Penetrating Cationic Miniature Proteins Reach The Cytosol Intact

A trivial explanation for the results obtained above is that cationic miniature protein 5.3
as well as Tat, and Arg8 are degraded by endosomal proteases, releasing the dexametha
sone label, which, by itself, can efficiently cross cell membranes and induce the nuclear
localization of GR-GFP. Thus, I sought to confirm that the peptide backbone of miniature
protein 5.3 is not degraded under the conditions in this assay, that is to say, within the 30
min incubation period after the peptides are added to HeLa cells and before they are an
alyzed by epifluorescence microscopy. To examine possible metabolism of 5.3, HeLa cells
were treated with 1

rhodamine labeled cationic miniature protein under conditions

analogous to those used for flow cytometry above (Fig. 3.3). The cells were then pel
leted, washed with PBS, and lysed using a detergent buffer. The insoluble material was
cleared from the lysate by a brief centrifugation (10 min, xoooog) after which the super
natant containing soluble cell lysate was diluted into 15% ethanol in water and injected
onto an HPLC fitted with a C8 (100 x 2.1 mm, 100A pore) collum. Because we expected
the concentration of this solution to be low, we employed a high sensitivity Shimadzhu
HPLC fitted with a fluorescence detector capable of sensing the presence of attomoles of
rhodamine. The fluorescence HPLC traces obtained are shown in figure 3.8. As can be
seen in panels a and c, the fluorescence chromatogram of miniature proteins obtained
from the cell lysate are virtually unchanged from the chromatogram on an input sample.
By contrast, the chromatograms of TatK and Arg8R show an increased number of peaks
in chomatogram obtained from lysate as compared to the chromatogram obtained from
the input sample.
It is likely in the above experimental set up that some of the peptide obtained after cell
lysis was bound to extracellular surface proteoglycans or was present in endosomes. We
addressed this issue in two ways. First, to emove peptide bound to the cell surface, we
repeated the above experiment, but included a brief incubation with trypsin following
peptide treatment to remove surface bound peptide (Fig. 3.9). While small amounts
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Figure 3.6: Translocation of GR-GFP after treatment with dexamethasone and dexlabeled miniature proteins, (a) HeLa cells transfected with GR-GFP (which appears
black) after treatment with 1
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Figure 3.8: Absence of degradation of cationic miniature proteins. 2 x 105 HeLa cells
were treated with 1 jj.M rhodamine labeled cationic miniature protein or peptide for 30
min in HKR buffer, before washing and lysis. Cell lysates were then examined by HPLC.
HPLC traces of cationic miniature proteins are essentially unchanged between the cell
lysate (black traces) and a control sample spiked with peptide not exposed to cells (red
trace). Cell lysate from HeLa cells treated with rhodamine labeled Arg8 or Tat show the
appearance of numerous additional peaks, indicating modification or degradation of the
peptide backbone.

55

1

0

rhodamine

,

rhodamine

1

rhodamine

rhodamine

RIPA buffer

RIPA buffer

RIPA buffer

RIPA buffer

aPPR

5.3r

Arg8R

TatR

RIPA lysate

t> — RIPA lysate
8
16

RIPA lysate

8

|

16 0

|

RIPA lysate

8

16 0

A.

8

16 0

time (min)

Figure 3.9: Absence of intracellular degradation of cationic miniature proteins. 2 x 105
HeLa cells were treated with 1
rhodamine labeled cationic miniature protein or pep
tide for 30 min in HKR buffer, washed twice and treated with 0.05% trypsin for 10 min
at 37°C, after which the cells were washed again and lysed in RIPA buffer. Cell lysates
were then examined by HPLC. HPLC traces of cationic miniature proteins are essentially
unchanged between the cell lysate (red traces) and a control sample containing the start
ing material but not exposed to cells (blue trace). RIPA buffer alone shows a single peak
(due to the presence of detergent, data not shown, grey traces). The retention time of
rhodamine alone is shown as a control (black trace).
of aPPR were recovered from cells after lysis and treated with trypsin (Fig. 3.9a), this
amount was increased for cells treated with 5.3s (Fig 3.9b). In neither case was material
with retention times distinct from starting material recovered. By contrast, multiple
peaks were detected in lysates from cells treated with Arg8R and TatK (Fig. 3.9c, d). These
data confirm the results above, and suggest that increased recovery from cell lysates is
due to the intracellular presence of 5.3. Further more, the miniature proteins studied are
minimally degraded within the time frame of the experiment.
Second, to specifically ask whether cationic miniature protein 5.3, Tat, or Arg8, were
present in the cytoplasm, we employed a cell fractionation strategy that exploits the bac
terial pore-forming toxin streptolysin O (SLO) [146]. This peptide inserts into cholesterol
containing membranes undergoing a conformational change [147] leading to oligomerization at 37°C creating membrane lesions that are approximately 20 nm in size[i48] and
are repaired in a Ca++ dependent manner[i49]. At 37°C, and in the absence of Ca++, the
presence of these membrane lesions leads allows soluble cytoplasmic contents to diffuse
into the surrounding media (or surrounding proteins to diffuse into the cell[i5o]), while
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larger organelles, and vesicles remain inside the cell. Thus incubation in the presence of
SLO allows one to recover the cytoplasmic contents of a cell without disrupting endosomal membranes or releasing lysosomal contents. Others have cautioned, however, that
even commercial preparations of SLO possess widely differing activities[i5i]. Incubation
of cells with excess peptide can lead to aggregation and pore formation independently
of cholesterol, decreasing the specificity of the process[i5i].
To verify that SLO induces cell permeabilization and to identify the concentration
required for efficient recovery of cytoplasmic material, we incubated HeLa cells with
various concentrations of SLO on ice using a protocol previously described[i52, 153,
154, 146]. In brief, HeLa cells were detached from the growth flask by incubation in
PBS containing EGTA/EDTA, washed and aliquoted into 96-well plates. The cells were
then resuspended in ice cold solutions containing 5 mM dithiothreitol (DTT) in PBS
with various concentrations of SLO added and incubated on ice for 15 min to allow the
peptide to bind to the cell surface. (The presence of DTT is required for reduction of
a critical cysteine within the SLO peptide[i55].) The cells are then washed with PBS
and shifted to 37°C to allow oligomerization of SLO inducing pore formation[i47, 148]
and releasing cytoplasmic contents. At this point, the cells can be pelleted and the
supernatant containing the cytoplasmic extract recovered or the cells within the pellet
tested further.
Following this protocol, HeLa cells were treated with PBS containing 5 mM DTT and
between 7 pg/mL and 180 pg/mL SLO, leading to between 49% and 99% permeabilized
cells (data not shown). HeLa cells treated with 20 pg/mL SLO showed between 85%
and 89% +PI cells (Fig. 3.10a), indicating that this concentration of SLO permeabilized
the majority of cells, that decreasing the amount of SLO would decrease the fraction of
cells permeabilized. Because little advantage would be gained by increasing the amount
of SLO, and due to the possibility of non-specific acitivity with higher concentrations,
we tested this concentration for the release of the lysosomal enzyme ^-hexosaminidase.
HeLa cell treated with PBS or PBS containing SLO as above were pelleted by centrifu-
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gation and the overlying supernatant recovered, while the cell pellet was then solubilized using a detergent (RIPA) buffer, which is known to release ^-hexosaminidase,
and in which this enzyme is active. Equal cell equivalents of supernatant from PBS
and SLO treated cells, as well as the cell pellet from SLO treated cells were diluted in
an acidic assay buffer containing 7.5 mM 4-nitrophenyl-N-acetyl-^-D-glucosaminide, a
chromogenic ^-hexosaminidase substrate. Hydrolysis by /5-hexosaminidase leads to re
lease of 4-nitrophenol, which absorbs 405 nm light, enabeling spectrophotometric quan
titation. After incubation at 37°C for 1 hr, the reaction is stopped and the absorbance
measured. The vast majority (>95%) of the enzymatic activity in SLO treated cells re
mained within the cell pellet (Fig. 3.10b), while only 2.5 ±0.1% of the ^-hexosaminidase
activity was present in the supernatant. These data indicate little, if any, permeabilization of the lysosomal membranes takes place when HeLa cells were treated under these
conditions. Because ^-hexosaminidase is present in early endosomes as well[i56], it is
unlikely that signficiant permeabilization of this compartment occurs. These data do not
exclude the possibility that permeabilization of the secretory organelles such as the endo
plasmic reticulum or the golgi apparatus occurs, however, using fluorescence microscopy
we do not observe fluorescence in these compartments (see Figs. 4.6 on page 109, 4.1 on
page 99, and 4.5 on page 108).
Having established that our SLO treatment protocol permeabilizes approximately
85% of the treated cells without disrupting endolysosomal membranes, we next asked
whether we could detect intact or degraded rhodamine labeled cationic miniature pro
teins within cytoplasmic extracts. 2 x 105 HeLa cells were treated with 1 pM aPPR, 5.3s,
5.2s, TatR, or Arg8R at 37°C for 30 min before washing and tyspsin treatment. Cyotplasmic extracts were generated using SLO as described above and examined by fluo
rescence HPLC. Little or no fluorescence was detectable in cytoplasmic extracts treated
with aPPR, while fluorescence peaks were identified in cytplasmic extracts generated
from cells treated with 5.3^, 5-2R, TatR, or Arg8R (Fig. 3.11). Comparing starting material
to recovered cytoplasmic extracts revealed that fluorescence material present in cytoplas-
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Figure 3.10: Confirmation that SLO induces cell permeabilization. (a) HeLa cells were
treated with PBS (control) or PBS containing 20pg/mL SLO (+SLO) for 10 min on ice,
after which they were washed and resuspended in PBS containing lpg/mL propidium
iodide. Exclusion of propidium iodide requires an intact cell membrane. Treatment with
SLO increased the fraction of PI positive cells from 7.6% to 85%. (b) SLO treatment does
not release the lysosomal enzyme ^-hexosaminidase. HeLa cell treated with PBS or PBS
containing SLO as in a were pelleted by centrifugation and the overlying supernatant
recovered. The cell pellet was then solubilized using RIPA buffer. Equal cell equivalents
of supernatant from PBS and SLO treated cells, as well as the cell pellet from SLO treated
cells were incubated with a chromogenic /^-hexosaminidase substrate. Enzymatic reac
tivity was assayed by increased absorbance at 405 nm. Greater than 90% of the enzymatic
activity in SLO treated cells remains within the cell pellet.
mic extracts from cells treated with TatR (Fig. 3-iid) or Arg8R (Fig. 3.ne) did not have
the same retention times as the starting peptides. This could indicate covalent modifica
tion of the peptide itself or strong non-covalent association of cellular protein, however
this latter possibility is unlikely because HPLC conditions (0.1% TFA in ACN/H20) are
strongly denaturing. Cytoplasmic extracts from HeLa cells treated with 5.3s or 5.2s each
showed single peaks of fluorescence material with retention times that matched starting
material (Fig. 3.11b,c). The area under the peak was larger for 5-3R than 5-2R, consistent
with the GR-GFP translocation assay (Fig. 3.6 on page 53) showing that greater nuclear
translocation is observed after treatment with 5.3s than with

5-2R.

After endocytosis, internalized material is exposed to proteolytic hydrolases within
the endolysosomal compartment, typified by the cathepsin family of acid-activated cys
teine proteases. We wondered whether the enhanced activity of 5.3^ within the GR-GFP
translocation assay might be due to differential resistance or sensistivity to these pro
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teases. The former could increase the effective concentration within the endosome, the
latter could release dexamethasone which is cell permeable. To distinguish between
these possbilities, we treated aPPR, 5.3s, 5.2s, TatR, and Arg8R with endosomal cathepsins B, D, and L for 30 min at 37°C in acidic (o.x M sodium citrate, pH 4.7) and reducing
(5 mM DTT) conditions. The reactions were stopped by cooling to 4°C and dilution in
0.1% TFA in ACN/H2O, prior to analysis by fluorescence HPLC (Fig. 3.11). Incubation
with Cathepsin D completely modified the cationic miniature proteins test as indicated
by the absene of any peak with the same retension times as the starting materials (Figs.
3.na,b,c), while little difference was observed following incubation of Cathepsin D with
TatR or Arg8R (Figs. 3.nd,e). Incubation of 5.2R with cathepsin B resulted in the gen
eration of multiple additional new peaks on the HPLC trace, although at the end of the
30 miri incubation signficiant starting material remained indicating partial modification
of this peptide (Fig. 3.11c). Similar results were obtained after incubation of 5.3^ with
cathepsin B, though the consumption of starting material was less extenstive (Fig. 3.11b).
Cathepsin L failed to modifiy any of the cationic miniature proteins tested, but did com
pletely consume Arg8R (Fig. 3.ne). No detectable modification of TatR took place after
incubation with cathepsins B, D, or L (Fig. 3.1id). These results indicate that digestion
products of aPPR, 5.3s, 5-2R, TatR, and Arg8R by endosomal cathepsins are readily de
tectable by HPLC, suggesting that were these present within cytoplasmic extracts they
would have been identified. Furthermore, because all cationic miniature proteins are susceptable to cathepsin B, these results decrease the possibility that the results observed are
due to the differential sensitivities of these molecules to endosomal degradation. Were
the results of the GR-GFP translocation assay due to release of dexamethasone follow
ing, for example, degradation of tj.zDex by cathepsin D, we would expect this molecule
to show more, rather than less activity than 5.3°^.
These results suggest that quantitative comparisons of the amounts of cytoplasmic
rhodamine labeled peptide should be possible by generating cytoplasmic extracts using
SLO and comparing the amount of recovered peptide by integrating the area under the
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Figure 3.11: Recovery of cationic miniature protein 5.3, unmodified, from the cytoplasm.
HPLC analysis of cytplasmic extracts generated using SLO from 2 x 105 HeLa cells
treated for 30 min at 37°C with a solution containing x pM of the indicated peptides
(green traces) are shown. HPLC alanysis of the purified peptides (starting material, red
traces) and rhodamine alone (black traces) are shown for comparison. In addition, reac
tions containing 50 pmol peptide and 5pg of the indicated cathepsin were incubated at
37°C for 30 min prior to HPLC analysis (blue, purple, and green traces).
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peak of the fluorescence HPLC trace. Data above support the hypothesis that these ex
tracts are not significantly contaminiated by peptide present in the lysosome or bound to
the cell surface. To quantitatively compare the relative fraction of 5-3R and 5.2^ released
into the cytoplasm, we treated duplicate samples with

ijiM

rhodamine labeled cationic

miniature proteins 5.3s or 5.2^ for 30 min at 37°C before either generating cytoplasmic
extracts using SLO or total cell lysate using RIPA buffer (Fig. 3.12). This process was
repeated in triplicate. Fluorescence HPLC traces for samples generated are shown in fig
ures 3.12b and 3.12c. Quantitative integration of the identified peaks (Fig. 3>i2d) in total
cell lysates showed that for cells treated with 5.2s or 5.3s, 11.7 it 0.8 pmol and 10.1 ± 0.3
pmol per 2 x 105 HeLa cells were recoved, respectively. Cytoplasmic extracts of HeLa
cells treated with 5.2s or 5-3R contained 0.31 ± 0.06 pmol and 0.44 ± 0.04 pmol per 2 x 105
HeLa cells, respectively. The fraction of 5.2s and 5.3R present in the cytoplasmic extracts
(as compared to the total cell lysate) are 2.64 ± 0.54% and 4.37 ± 0.32% respectively, nearly
66% more for 5.3** than 5.2s (p = 0.0516). The variability in these measurements makes
quantitative comparisons preliminary, as the difference, though showing a strong trend, is
not statistically significant.
This indicates that peptides TatR and Arg8R are degraded or otherwise altered by
the cells within the time course of these experiments. On the other hand, 5.3s remains
unchanged.
Taken together these results support the conclusion that treatment with 5<3Dex in
duces the activation and nuclear translocation of GR-GFP because this peptide possesses
an array of arginine residues that serve to target it to the cytoplasm.

3.2.6

Cationic Miniature Protein 5.3 is a monomer

Avian pancreatic polypeptide dimerizes[i57,158] in solution with a dissociation constant

KD = 4.1 x 10

6M 1

at pH 7U30]. It is possible that the incorporation of arginine

residues leads to protein that is poorly behaved in solution. Aggregated protein can be
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Figure 3.12: Direct observation that the 5.3 motif increases the cytoplasmic presence of
miniature proteins, (a) Schema. Duplicate samples of 2 x 105 HeLa cells were treated
with ijjM rhodamine labeled miniature protein for 30 min at 37°C. The cells were washed
with 150PL PBS, then treated with 0.05% trypsin for 10 min at 37°C, and washed a second
time. To generate total cell lysates, the sample was lysed by the addition of 4011L RIPA
buffer and incubation on ice for 30 min. To generate cytoplasmic extracts, the cells were
incubated with 5OJ1L of an ice cold solution containing 2opg/ mL SLO and 5 mM DTT in
PBS for 15mm at 4°C. The cells were washed twice with l^opL of PBS before warming to
37°C to allow pore formation. The cell pellet was separated from the cytoplasmic extract
by centrifugation (2 min x 300g). HPLC traces of RIPA and SLO extracts from HeLa
cells treated with (b) 5.2s or (c) 5.3s. The retention time of the starting peptide is shown
by the vertical dashed grey line. The latter peak in the RIPA samples is due to light
scatter from the presence of detergent, (d) Quantitative analysis of recovered peptide.
The total amount of peptide recovered in RIPA and SLO extracts from samples is shown,
based on standard curves generated from injecting known quantities of rhodamine and
integrating the area under the major peak, (e) The fraction of peptide released into the
cytoplasm, i.e. the fraction of peptide in the SLO sample compared to the RIPA sample,
is shown for each of three replicates.
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toxic to cells, and the aggregation of arginirie rich peptides on the surface of cells can
cause membrane disruption[i26,125]. While I previously showed that treatment of HeLa
cells with 1

5.3°" did not cause membrane disruption, I asked whether, at similar

concentrations, 5.3 existed in a different associated state than other miniature proteins.
I also wished to draw a comparison between the association state of unlabeled 5.3 and
when labeled with dexamethasone, to understand whether installing the dexamethasone
label altered the association state.
To accomplish this task, we turned to analytical ultracentrifugation (ALOU59], a
well-established method to determine the association state of proteins[i6o], including
aPP[i57], In this method, sample solutions containing protein are placed under a cen
trifugal force. After equilibrium is reached the concentration of protein as a function of
the rotational radius (and thus angular velocity, co) is determined using a spectropho
tometer. The equilibrium profile obtained (usually plotted as protein concentration vs
radius) depends on relative buoyant densities of the protein (v) and solution (p), as well
as the diffusion rate of the protein (D), which is sensitive to molecular size. The dif
fusion rate and the buoyant density are sensitive to oligomerization state. Obtaining
sedimentation profiles under several different angular velocities allows fits to models
using available software[i6i, 162].
The simplest model of sedimentation begins with a single ideal species, whose con
centration at radius r from the center of rotation defines a sedimentation profile depen
dent on v, p, to, and molecular weight (M) as follows:

C(r) = C(r0)eM(1-^)f1^
A general monomer-nmer self-associating system (n • A ^ A n ) results in a superposi
tion of two sedimenting ideal species (one with the molecular weight of the monomer,
the other with a molecular weight n times larger), whose concentrations at all points
along the solution column satisfy the law of mass action, and thus define an association

64

constant (Ka).
The examination of aPP by analytical ultracentrifugation has been previously reported[i30,
157,158]. Therefore we began by repeating the equilibrium sedimentation (Fig. 3.13) in
the previously reported buffer (phosphate buffered saline, PBS), as well in the buffer used
for the above studies of protein uptake (HKR buffer). Analysis of aPP in PBS showed
self-association (fig. 3.i3b-d). The single ideal species whose sedmidentation best-fit the
data has a molecular weight of 8501 (which is 2.01 times the actual molecular weight of
aPP, fig. 3.13b). Fitting the equilibrium sedimentation profiles to a monomer-dimer equi
librium (fig. 3.13d) yields lnKa = 15.608, which corresponds to a dissociation constant,
Kp = 1.66 x 10~7 M. Repeating this analysis with aPP dissolved in HKR buffer, resulted
in a sedimentation profile that also showed self-association. The molecular weight of a
single ideal species that best fit the sedimentation profile was 8313 (1.96 times the molec
ular weight of aPP, fig. 3.13^- Fitting the sedimentation profile to a monomer-dimer
equilibrium (fig. 3.13b) yielded In Ka — 15.726, or Kp = 1.48 x 10~7 M. These values
are within the range previously reported (Kp = 5 x 1(T6 to 2 x 1(T8 M) [158, 130]. To
test whether the installation of the dexamethasone label leads to a change in the asso
ciation state, we repeated the above analysis using aPPDex. This molecule also showed
self-association (best-fit single ideal species MW = 12080, fig. 3-i3j), however fitting the
sedimentation profile to a general monomer-'Nmer' model revealed that the association
was less energetically favorable. The model showing the best fit to the sedimentation

Figure 3.13 (following page): Analysis of aPP and its dexamethasone labeled variant by
analytical ultracentrifugation. The buoyant density of aPP (a and e) and aPPDex (i) were
calculated according to the method of [163], while the density of the solutions were
calculated based on the buffer components using the program SEDNTERP. The sedi
mentation profiles of aPP in PBS (b, c, d) and HKR (f, g, h) buffers as well as aPPDex
in HKR buffer (j, k, m) after reaching equilibrium at 36,000, 42,000 and 50,000 rpm are
shown. Fits to single sedimenting species (b, f, j) and general monomer-oligomer (c, g,
k) are shown. For each general monomer-oligomer model, the sedimentation profiles
were fit to an integer association state (d, h, m) closest to the best-fit variable n from the
monomer-oligomer model. The residuals from each fit are shown below the graph of the
sedimentation profile.
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profile was a monomer-trimer equilibrium, with lnJ«Cfl = 18.620 (fig. 3.13m), which cor
responds to a binding isotherm showing an inflection point (the concentration at which
50% of the miniature protein is monomelic) at 5.23 x 10~5 M. To aid in interpretation
of these numbers we modeled the association states (see fig. 3.14) of aPP and aPPDex
as a function of concentration, comparing results when using equilibrium constants pre
viously reported[i3o]. The curves using the values for aPP in PBS and HKR buffers
(determined in this study) overlap nearly completely (fig. 3.14a). The values determined
previously show less extensive association of aPP at similar concentrations. The dex
amethasone modified variant, aPPDex remains at least 99% monomeric at concentrations
up to 5 f/M. Thus, under the conditions used above, when aPPDex is added to cells at a
concentration of 1 jiM, the protein is monomeric.
We next set out to assess whether, when added to cells in the conditions used above,
cationic miniature proteins 5.3 and 5.3°^* were also monomeric. Examination of 5.3 and
5.3°" revealed that both of these miniature proteins weakly self-associate. Beginning
with a model of a single ideal species and allowing the molecular weight to vary, the
sedimentation profiles fit best to species of molecular weight significantly higher than
the actual molecular weights of the miniature proteins. Using a general fitting strategy
where the association state, n, and In Ka are optimized yielded oligomerization states of
3.79 and 2.84 for 5.3 and 5-3°ex respectively. Fitting the sedimentation profiles to integer
association states (i.e. 4 in the case of 5.3 and 3 in the case of 5-3Dex) yields a monomertetramer fit for the sedimentation profile of 5.3 with In Ka = 31.995, while a monomertrimer fit for the sedimentation profile of 5.3°" yields In Ka = 21.029. The concentrations
at which 50% of the miniature proteins 5.3 and 5.3°" are present as monomer are 15.7
and 17.9 ^M, respectively. At the concentration used in the studies above (i.e. 1 jtM),
both the dexamethasone-labeled and unlabeled miniature protein are > 99% monomeric.
Thus there is little, if any, difference in the association state between aPPDe* and 5.3°"
at the concentrations used. This data support the conclusion that the installation of
arginines on the helical portion of 5.3 result in its uptake and cytoplasmic localization,
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and that this effect is not due to change in the oligomerization state of the protein.
We found that at 1

all three miniature proteins (aPP, 5.3, and 5.3°") are pre

dominantly monomeric. Comparing the modeled transitions of 5.3 and 5.3°" results
in nearly complete overlap, indicating that the weight fraction of monomeric miniature
protein is not altered by the addition of the dexamethasone. Furthermore, at 1 ^M, the
concentrations at which these proteins are applied to cells, these miniature proteins are >
99% monomeric. Thus cationic miniature protein 5.3 is a monomer in solution at the con
centrations used in these studies, and this conclusion is not dependent on the presence
or absence of the dexamethasone label.

3.2.7

Natural Helices containing Arginine

The results reported here suggest molecules that contain a discrete a-helical arginine
array can hijack endocytic machinery to cross into the cytosol. We wondered whether
a similar a-helical arginine array might be found in natural proteins whose biological
role demands the perturbation of membrane structure. Alternatively, if we found helical
arginine arrays in proteins not known to interact with membranes, it would raise the
possibility that membrane interaction was an unrecognized function.

3.2.7.1 An arginine-rich helix search
We began searching the PBD database for structures containing helices by extracting the
amino acid sequence for each helix from the structure file. Structures deposited before
1995 were not analyzed, because these structures do not include records for secondary
structure. My search yielded a list of 360,446 helical sequences from 37,479 peptide
chains. Many of these represent reflected or homo- and hetero-oligomerized protein
chains within the crystallographic asymmetric unit, and therefore share the same se
quence as another helix within the same structure. After filtering out these occurrences,
we are left with 217,015 helical sequences.
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Figure 3.14: Association states of aPP and aPPD" as they vary with concentration. A
self-consistency modeling approach was utilized to determine the weight fractions of
monomeric (closed circles) and oligomeric (open circles) miniature protein by solving the
mass action equation for self-associating systems at total protein concentrations between
10~10 and 10~3 M. The concentration used when studying the effects of peptides on cells
(1 piM) is shown with a dotted green line. The parameters for aPP in either PBS or
HKR buffer and aPP0e* in HKR buffer were determined from the data shown in figure
3.13. The parameters for aPP in Tris-buffered saline (TBS; 25 mM Tris, 50 mM NaCl,
pH 8.0) were reported previously[i3o]. (a) At similar concentrations, the fraction of
oligomeric aPP is similar in PBS (blue) and HKR (orange) buffers, but lower in TBS. (b)
Miniature protein aPP Dex is monomeric at the concentration used in these studies. [The
Excel program for modeling the assembly of oligomers was contributed by Cody Craig.]

Figure 3.15 (following page): Cationic miniature protein 5.3 and its dexamethasone la
beled variant are monomers. Physical parameters of 5.3 (a) and 5.3°" (e) calculated by
the method of [163]. The density of the solution, p, was calculated based on buffer com
ponents using SEDNTERP. The sedimentation profiles of 5.3 (open circles, b, c, d) and
5-3Dwt (open circles, f, g, h) after reaching equilibrium at 36,000, 42,000, or 50,000 rpm are
shown, (b) Best-fit monomer-tetramer model (lines) and residuals (below). The residu
als do not show systematic deviation. The fit yeilds lnJKfl = 31.395. (c) Residuals from
a model single ideal species shows systematic devation and a molecular weight higher
than 5.3 indicating self-association, (d) A general monomer-nmer model fit reveals an
association state n — 3.79 ± 0.03. (f) Best-fit monomer-trimer model (lines) and residuals
(below). The residuals do not show systematic deviation. The fit yeilds lnK„ = 21.029.
(g) Residuals from a model single ideal species shows systematic devation and a molec
ular weight higher than 5.3°" indicating self-association, (h) A general monomer-nmer
model fit to these data reveals an association state n = 2.84 ± 0.01. (i) Summary table
of the derived parameters from fitting sedimentation equilibrium profiles. For compari
son, the values for aPP, reported by [130] are shown. (j)The weight-fraction of miniature
protein existing as a monomer (closed circles) or in an oligomeric comples (open circles)
in solution as a fuction of concentration. These data are modeled based on parameters
shown in i. [The Excel program modeling fraction monomers was contributed by Cody Craig.]
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appDex

To search for sequences enriched in arginine, we used a sliding window approach
in which the number (and orientation) of arginines was tabulated within an 18 amino
stretch, the length of the helix in 5.3. Of the 216,876 helical sequences, I found 2,531
that contained 4 or more arginines: 1649 sequences contained 4 arginines within an 18
amino acid window, while 399 contain 5 or more arginines. We next looked for helices
in which the arginines were clustered in the same side of the helix. Over short stretches,
the position of amino acids within a-helices show a seven-fold repeating arrangement
over two turns of the helix, so that starting with position i on the first turn, i + 3, i + 4,
are closely apposed on the rung above. Position i + 7 is oriented above position i. Using
the positional index of arginines and taking the numerical indices modulo 7, we filtered
the arginine rich helices for those members that contain 4 or more arginines in the i,
i + 3, and i + 4 position for any i along the helix length. We found 1484 helical sequences
(derived from 449 structures) that fulfill these criteria. Because these sequences contain
at least one set of three adjacent faces with a total of 4 arginine residues, they can be seen
as variants of miniature proteins 4.3. This conception would place miniature proteins 4.2
and 5.2 as subsets of the 4.3 and 5.3 family. However, because these variants were less
effective at obtaining cytosolic access, I chose to consider them separately. Filtering the
above 449 structures for members containing exactly 4 or 5 arginine residues on three
helical faces yields 14 protein chains containing 5 arginine residues within a window of
18 amino acids arranged on 3 helical faces. Interestingly, none of these proteins contained
the exact arginine arrangement seen in 5.3 (arginines located in positions i, i + 4, i + 7,
i + 10, and i + 11). A similar search for proteins containing exactly 4 arginines within
an 18 amino acid window and located in i, i + 3, and i + 4 positions yielded 167 hits,
identifying these proteins as members of the 4.3 family.

3.2.7.2

Functions of natural arginine rich helices

The list of 5.3 motif-containing natural proteins contains too few members to quanti
tatively confirm or deny the our hypothesis that this filtering algorithm enriches for
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Figure 3.16: Schema for the identification of arginine-rich helices from the PDB. The
entire PDB is searched for helical segments (1), which are then filtered for duplicated
sequences within the same structure (2) and sorted based on arginine content (3). Out of
216,876 helical sequences, 2,048 unique sequences contain >4 arginine residues within an
18 amino acid window. Helical chains were then sorted as 'clustered' or 'unclustered',
(4), a shown in the helical diagram. (5) 1172 sequences contained exactly 4 arginines,
dispered across the entire helical surface. These were excluded from further analysis
because they do not conform to the arrangement of arginines in 4.3. (6) Sequences con
taining >4 clustered arginines aranged on exactly two faces were designated 'R.2-like',
whereas sequences containing arginines arranged on exactly 3 faces were designated
'R-3-like', where R is the number of arginine residues in the helix. These were filtered to
exclude mutliple sequences from the same structure. (7) Results of the helix search: 239
4.3-like proteins and 14 5.3-like proteins were identified.
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membrane-perturbing proteins. Members include a transcription factor (the thyroid nu
clear hormone receptor) and several ribosomal proteins. It is unsurprising that proteins
whose biological role is the interaction with negatively charged nucleic acid include pos
itively charged segments. None the less, it is intriguing to observe that this set also
includes CHMP3[i64], a member of the ESCRT-III complex involved in membrane scis
sion whose a-helical arginine array (identified in our search) is essential for its interaction
with cellular membranes and ESCRT-III function[i65]. The presence of the adenomatous
polyposis coli (APC) tumor suppressor gene in our hit list is also intriguing. This pro
teins interacts tightly with the cytoskeleton at adherens junctions through a complex
that includes Cdc42 and Raci, proteins that link the process of endocytosis to the actin
cytoskeleton. A previous study identified the activity of Raci as required for the actin
reorganization that precedes the uptake of Tat and Arg8.
Broadening the search to examine the list of 4.3 motif-containing natural proteins re
sults in additional insight, and strengthens the hypothesis that arginine rich helices inter
act with the actin cytoskeleton and are active motifs for uptake. Proteins containing argi
nine rich segments that play a role in the endocytic machinery either directly or through
interaction with actin include complexin, spectrin alpha chain, phosphatidylinositolbinding clathrin assembly protein (CALM, a homolog of AP180), vinculin, and PLEKHA4,
a PI3P binding protein. Also identified was BipD: a self-chaperoning protein found on
the needle tip of the type 3 secretion system.
Literature searches illustrate the functional involvement of regions in which acidic
residues are found, there are few examples of studies mutating arginine residues specifi
cally. In the case of BipD, the helices in which the acidic residues are found are predicted
to undergo a conformational shift, during the activation of the 'needle' to translocate vir
ulence factors into target cells[i66]. In the case of vinculin, the basic residues surround a
patch that interacts with phosphoinositi.des[i67]. In the case of CALM, these are not re
quired for binding to PI(4,5)P2 [168,169,170], but comprise the c-terminus of the CALM
proteins ANTH domain and are conserved between CALM and AP180. Four arginine
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PDB CODE

UniProt Accession

UniProt Name

Arrangement

Sequence
_

Cationic Miniature Protein 5.3 {thisstudy)
Charged multivesicular body protein 3 (CHMP3)
Ribosome-recyding factor
60S ribosomal protein L30
Protein CBFA2/Fusion Protein AML-ETO
HLA classIhistocompatibility antigen, alpha chain E
Adenomatous polyposis coli protein
Thyroid hormone receptor beta
Ribosome-recyding factor
Ribosome-recyding factor
Ribosome-recyding factor
30S ribosomal protein S7
DNA nudeotidylexotransferase
Carboxypeptidase 1, unreviewed
Heat shock cognate 71 kDa protein (Hsc70)

abc defg
2001200
1200200
2003000
2002001
0003200
1002002
2002100
0021002
3100100
3100100
3100100
1003100
0310010
2002100
0020012

RDLIRFYRDLRRYLNW
RKEXRWDRQIRDIQREE
RAVRQYAEEGRVAIRNIR
RLILVESRIHRLARYYKR
EKTRRSLTVLRRCQEADR
RETRSARDTAQIFRVNLR
RAQRRIARIQQIEKDILR
SKRLAKRKLIEENREKRR
RGEAEQARVAVRNVRRDA*
RGEAEQARVAVRNVRRDA*
RGEAEGGRVAVRNIRRDA
RPVRRNALAMRWIVEAAR
SRQFERDLRRYATHERK
EYERGIVRVLDRSIRIAR
NKRAVRRLATACERAKRT

Histone H3
Translocator protein BipD
Vinculin
Pleckstrin homology domain-containing family A member 4
VP16

0012001
1002001
1002001
0020011
0011002

PVGRVHRLLRR
TVFDDARVAVRGHARAQR
GATSIARRANRILLVAKR
TLEDLRGWLRALGRASR
FCSALYRYLRASVRQLHR

5.3-like protiens
--

--

2GD5
1EH1
1YSH
1WQ6
1MHE
1M5I
3M9E
1Y69
1EK8
1IS1
2WWL
1KEJ
1KA2
1QQN

Q9Y3E7
Q9WX76
Q5I7K9
Q06455
P61769
P25054
P18113
P0A807
P0A805
Q8GRF5
P0A7W7
P09838
Q8U3L0
P19120

4.3-like protiens (selected)
1ID3
3NFT
1TR2
1UPQ
16VP

P61830
Q63K37
P18206
Q9H4M7
P06492

Figure 3.17: Natural proteins containing arginine-rich helices identified from searching the PDB. Proteins containing helical seg
ments that are consistent with the 5.3 and 4.3 motifs are shown. The PDB code for each protein, the corresponding Uniprot
accession number, and the protein name are shown together with the number of arginine residues in each helical postion as well
as the amino acid sequence of the arginine rich segment.

residues also present within the same c-terminal region of the ENTH domain but these
residues are split over two-helices with a kink in the middle. The biological function and
the identity of the lipid interacting residues of PLEKHA4 remain untested.
Whether or how these proteins utilize arginine rich helices remains unknown. Argi
nine rich helices may play a specific role in modifying membrane structure through inter
action directly with lipid, or may serve other functions. Drawing functional comparisons
between cationic miniature proteins and natural cytoplasmic proteins that contain argi
nine rich helices is complicated by the fact that these proteins exist (at least initially) on
the opposite side of the cell membrane. Nonetheless, the presence of cytoplasmic pro
teins that contain this structural motif is encouraging. The role of BipD may be more
analogous to cationic miniature proteins because it functions on the extracellular face of
membranes. Experimental comparisons may reveal unknown functions of basic residues
within the type 3 secretion system, alternatively studying the mechanisms of proteins
containing arginine rich helices may reveal clues that improve our ability to design cytosolic miniature proteins.
Thus, compared to searches looking only for overall positive charge[ii9, 1x8], our
analysis of structural determinants for miniature protein entry greatly expands the num
ber of potential proteins in nature that may contain cell-penetrating or at least mem
brane-perturbing function. The ability of cationic miniature protein 5.3 to rapidly es
cape from early endosomes is a unique feature, not shared by canonical cell penetrating
peptides, and represents a starting point for the optimization of well-folded functional
cell penetrating proteins useful as pharmacologic tools capable of modulating cytoplas
mic protein function. More sophisticated comparisons than the one presented here may
illuminate shared features of these and other arginine rich proteins.
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3.3

Discussion

The interfaces that form between and among proteins and DNA-often large, flat, and polar-do not resemble those that bind small molecule substrates or traditional irihibitors[i32]
Targeting these 'undruggable' interfaces is a task well suited to protein and peptide ligands, but can only be successful if such molecules reach their cytosolic targets. Unfor
tunately, the very properties that endow peptide mimetics with their promise-size and
polarity-are precisely those properties forbidden by Lipinski's rules[2]. The challenge,
therefore, is to identify the determinants that guide the uptake of peptide-like molecules
and the mechanisms through which they gain cytosolic access, generating a new set of
rules applicable to large peptidic molecules. Advancing this goal has been constrained
by the absence of a rapid and robust assay capable of distinguishing between peptide-like
molecules trapped within endosomes or those that have escaped into cytosol.
Here we took advantage of previous observations that the cytoplasmic-to-nuclear
translocation of the glucocorticoid receptor (GR) takes place within minutes[i44] and
recent developments in automated high-content image analysis, to develop an assay that
exploits the nuclear to cytoplasmic ratio of a GR-GFP fusion protein as a proxy for the
cytoplasmic entry of traditionally impermeant molecules tagged with dexamethasone.
Compared with a first-generation assay developed by Kodadek and colleagues[i43], the
one reported here provides a readout in intact living cells within 30 min (as opposed
to 48 hours) using an epifluorescent microscope and eliminates the requirement for cell
lysis or enzymatic substrates, substantially reducing cost.
Beginning with a panel of miniature proteins that contained variety in the number
and orientation of arginine residues, I found that the structure of the miniature protein
scaffold aPP was tolerant to incorporation of up to five arginine residues. Next, by
synthesizing fluorescently labeled variants, I found that the incorporation of arginine
resulted in molecules that were taken up more efficiently by cells that the parent molecule
aPP. For molecules containing four arginines, the magnitude of the effect dependend on
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the relative orientation of the positively charged residues, with the clustered arginines
present in 4.2 resulting in greater uptake than the more dispersed arginines found in 4.3.
In the case of molecules containing five arginines, the magnitude of the effect was similar
regardless of their orientation.
Among the four miniature proteins I identified as being actively taken up by cells, I
found clear differences in the ability to activate the GR when covalently linked to dexam
ethasone. GR activation by dexamethasone-labeled peptides and miniature proteins im
plies their presence in the cytoplasm. An alternative hypothesis is that the peptides and
miniature proteins studied are substantially degraded during the course of the experi
ment, leading to spurious activation of the GR by released (and perhaps cell permeable)
dexamethasone-peptide fragments. HPLC analysis of aPPR and 5.3s recovered from cell
lysates (Fig 3.8) shows that miniature proteins remain unmodified during the course of
the experiment excluding this possibility. Thus, the activation of the GR is due to the
arrival in the cytoplasm of the intact miniature proteins, and not due to the effect of a
degradation product.
For many cell penetrating peptides, cellular uptake results from an endocytic process
leaving the peptides trapped within a membrane bound endosome and unable to reach
their cytosolic target. It is tempting to invoke a hypothesis that endosomes are 'leaky' and
that peptides escape to the cytoplasm with similar rates. Even if this were this the case,
the differences in GR activation by 4.2°^*, 4-3Dex, 5.2°" and 5.3°" are not explainable
by differences in their endocytic rate (4.2s, 5.2s, and 5.3s are each taken up to a similar
extent). Indeed 4-3R is taken up to a lesser extent than 4.2s, but 4.3°" is a superior
activator of GR than is 4.2°", though the difference is small. Differences in affinity for
the GR receptor itself also do not explain these differences, as the in vitro affinity of 4.2°"
and 4.3°" for the GR is similar. A parallel argument holds true for peptides 4.2 and 5.3:
both are taken up to a similar extent, but treatment with lpiM 5.3°" leads to greater
activation than does treatment with /\.zDex. This comparison is strengthened by the fact
that 5-3°ex has a decreased affinity for the GR, requiring a higher effective concentration

77

to achieve the same fractional occupancy. Taken together, these findings identify 5.3 as a
cationic miniature protein capable of efficiently reaching the cytosol without disrupting
the cellular membrane.
How do the findings of 5.3 compare to cannonical peptides used to impart cytosolic
access? This comparison is somewhat complicated by the fact that lysates from cells
treated for 30 min with TatR or Arg8R show the appearance of degradation products.
This raises the possibility that the GR induction seen after treatment with TatDex or
Arg8Dex may be, in part, due to the action of degradation products rather than the intact
peptide. These data do not distinguish whether the eventual degradation of TatR and
Arg8R takes place within endosomes or the cytoplasm. If these molecules are degraded
within the cytoplasm, they may remain useful as modules to direct peptidomimetics to
cytoplasmic targets. The observed instability of Tat and Arg8 stands in contrast to the
stability of 5.3, a benefit of well-folded miniature proteins. This caveat not withstanding,
direct comparisons of 5.3Dex to TatDex and Arg8Dex reveal that translocation ratios are
similar for 5.3°" and TatDe* (p — 0.147), but that the translocation ratio after treatment
with S-3°ex is higher than after treatment with Arg8Dex (p = 0.3 x 10~9) suggesting that
Arg8 is less efficient at reaching the cytoplasm.
Comparison among these three peptides further supports the conclusion that inter
nalization and cytoplasmic access are separable, as cellular uptake of Arg8R is superior
to TatR, both of which are inferior to 5.3s. Thus, some of the peptides studied here
contain arginine motifs that display only efficient uptake (4.2, 5.2) or only cytoplasmic
localization (Tat). While Arg8 is intermediate in both uptake and cytoplasmic access,
miniature protein 5.3 effectively combines both of these features and displays increased
proteolytic stability. These comparisons reveal that the process of cellular uptake and
cytoplasmic access are governed by discrete structural determinants and that peptides
and miniature proteins may be optimized to possess either or both of these functions.
In summary, this study led to the identification of 5.3, a cationic miniature protein
whose rapid cytosolic localization is equivalent to or better than Tat and Arg8. This
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comparison revealed that contrasting structural determinants control cellular uptake and
cytoplasmic localization. Uptake is favored by clustered a-helical arginine side chains,
whereas cytoplasmic access requires a more dispersed arginine array.
How can the arginine residues mediate cytosolic localization? The differences in arginine/lysine number and orientation in 5.3, Tat, and Arg8 can affect side chain pKa (and
thus overall charge at a given pH), the ability to form neutral ion pairs with phospho
lipid head groups, or affinity for as-yet-unidentified cellular targets. How this difference
in charge state and or distribution could result in increased cytosolic access is unknown.
If these molecules are internalized into endocytic vesicles, it is possible that the distinct
arginine array in 5.3 favors the formation of a critical protonated species in the moder
ately acidic environment of the early endosome (pH « 6.5). Tat and Arg8 on the other
hand, may require the lower pH present in lysosomes inorder to generate an equivalent.
It is equally possible that the discrete arginine array in 5.3 represents an specific export
signal for cellular machinery that has not yet been identified.

3.4
3.4.1

Experimental Methods
Miniature protein synthesis and purification.

All miniature proteins and peptides were synthesized using a Liberty Automated Mi
crowave Peptide Synthesizer (CEM) and standard solid phase synthesis techniques. Cou
pling reactions were performed using 5 equivalents of amino acid, 5 equivalents HBTU,
and 10 equivalents of diisopropylethylamine in DMF. FMOC groups were removed us
ing 20% piperidine in DMF containing 0.1 M HOBT to minimize aspartamide forma
tion. Following synthesis, the peptides were cleaved from the resin by adding 5 mL
of a solution containing 95% TFA, 2.5% water, 2.5% TIPS and incubating at 38°C for 30
min using a microwave accelerator (MARS system, CEM). The solution containing the
crude peptide was precipitated by the addition of 40 mL cold ether. The precipitate
was dried under a nitrogen stream and lyophilized before purification via reverse phase
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HPLC (YMCbasic column, 150mm x 10mm ID) using a linear gradient of CH3CN in
water (both acidified with 1% TFA). Purified miniature proteins or peptides were col
lected and lyophilized, then reconstituted in water and kept at -4 °C protected from
light. The purity and identity of purified miniature proteins was characterized by ana
lytical HPLC (>95% in all cases) and either a Voyager (Applied Biosystems) MALDI-TOF
(matrix-assisted laser desorption-ionization time-of-flight) spectrometer (337 nm laser,
a-cyano-4-hydroxycinnaminic acid matrix), or a Waters QTof LC-MS. For molecular for
mulas, calculated masses, and measured (m/z) ratios of polypeptides and miniature
protein domains see figure 3.20. Labeled miniature proteins and peptides were assessed
for purity by analytical HPLC. Peptides and miniature proteins were injected on a Shimadzhu HPLC equipped with a fluorescence detector, a UV-Vis detector and fitted with
an Agilent Poroshell 120 SB-C18 column (100 mm x 3.1 mm ID, 2.7 pm particle size). A
linear gradient of 10 - 100% CH3CN in water (both acidified with 0.1% TFA) was used
as a solvent system. Fluorescein labeled compounds were detected via fluorescence (ex
citation 450 nm, emission 500 nm). Rhodamine labeled compounds were detected via
fluorescence (excitation 550 nm, emission 580 nm). Dexamethasone labeled compounds
were detected via absorbance at 280 nm. Traces are shown in figure 3.18 and figure 3.19.

3.4.1.1 Fluorescein labeled miniature proteins.
Fluorescein labeled miniature proteins were generated from purified peptides containing
an appended C-terminal cysteine residue. The purified unlabeled product was reacted
with 5-(iodoacetamido)fluorescein to generate the fluorescein-labeled miniature protein
as follows: to 500 ^L of a 100 mM phosphate buffer, pH 7.25 was added 1 jjmol of
the miniature protein, then water to a total volume of 2.5 mL. Separately, 5 mg of 5(iodoacetamido)fluorescein (Sigma Cat. #19271) was dissolved in 2.5 mL DMF. This DMF
solution was added to the aqueous miniature protein solution and the reaction was in
cubated in the dark at 25 °C for 2 hours. To generate unlabeled miniature proteins, the
C-terminal cysteine was capped by reaction with iodoacetamide under analogous con-
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Figure 3.18: HPLC analysis of selected cell permeable miniature proteins.
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ditions. The reaction mixture was purified using reverse phase HPLC using the column
and solvent system described above.

3.4.1.2

Rhodamine labeled miniature proteins and peptides.

Rhodamine labeled miniature proteins were generated by carrying out labeling reactions
on resin using an appended N-terminal lysine. For this purpose we employed an amino
acid monomer in which NK is BOC-protected and N£ is protected with an FMOC group.
The Ne was deprotected using microwave acceleration and incubating the resin twice
with 20% piperidine in DMF at 8o°C for 7 min. The resin was then washed thoroughly
with DMF. To label peptides with tetraethyl rhodamine, to the deprotected resin was
added 10 eq of Lissamine Rhodamine B sulfonyl chloride and 10 eq of diisopropylethylamine in 5 mL DMF at room temperature overnight. The resin was thoroughly washed
with DMF and DCM before global deprotection and cleavage using the conditions for
unlabeled peptides described above. Crude rhodamine labeled peptide was precipitated
in 40 mL of cold ether and lyophilized. Peptides were purified by reverse phase HPLC
as described above. Peptides lyophilized from HPLC solvents were stored in water at
4°C protected from light.

3.4.1.3 SDEX labeled miniature proteins and peptides.
SDEX labeled miniature proteins and peptides were generated in a manner analogous
the generation of rhodamine labeled miniature proteins; after appending an N-terminal
lysine residue bearing an FMOC protecting group in the side chain, the Ne was depro
tected using microwave acceleration by incubating the resin twice with 20% piperidine
in DMF at 8o°C for 7 min. The resin was then washed thoroughly with DMF. To the
deprotected resin was added 5 eq SDEX, 5 eq HATU, 5 eq of HOAT, 5 eq of DIPEA, and
5 eq of 2,6-lutidine in 5 mL DMF. The reaction was shaken overnight at room tempera
ture. The resin was thoroughly washed with DMF and DCM before global deprotection
and cleavage using the conditions for unlabeled peptides described above. Crude SDEX
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labeled peptide was precipitated in 40 mL of cold ether and lyophilized. Peptides were
purified by reverse phase HPLC as described above. Peptides lyophilized from HPLC
solvents were stored in water at 4°C protected from light.

3.4.2

Concentration Determination.

Concentrations of labeled miniature proteins were calculated using the extinction coef
ficients of the strongest absorbing chromophores. In the case of unlabeled miniature
proteins, the extinction was determined directly from the amino acid sequence3_ In the
case of labeled peptides, fluorescein

absorption at 500 nm in 8 M urea, 100 mM Tris-

HC1, pH 9.0 was measured using the molar extinction coefficient 78,000 M-1cm_1 at
500 nm (Invitrogen). The concentration of rhodamine labeled variants was determined
in water using an extinction coefficient of 87,000 M-1cm-1. The concentration of SDEX
labeled variants were determined using an extinction of 12,000 M_1cm_1 at 242 nm in
DMSO[i7i].

3.4.3

Circular Dichroism.

CD spectra of unlabeled peptides were recorded from samples containing 25 ^M peptide
in PBS as described[62].

3.4.4

Activation of GR by dexamethasone labeled peptides and miniature
proteins.

HeLa cells transfected with PK7-GR-GFP for 24 - 36 hr were plated (104/well in 200
ViL)

the day prior to experiments in 96 well glass bottom plates (Matrical). The media

was replaced with HKR buffer containing 300 nM Hoescht and the cells incubated for
30 min at 37°C. The media was then replaced with 150 jiL HKR buffer or HKR buffer
containing 1 jiM dexamethasone labeled cationic miniature protein or peptides or 1 ^M
dexamethasone as a positive control. The cells were incubated for a further 30 min at
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37°C before epifluorescence imaging using a Zeiss Axiovert 200M microscope fitted with
a mRM digital camera, a 63 x 1.3NA PlanApo objective and an EXFO-Excite illumination
source. Dual color epifluorescence images were acquired using the following filter sets:
Hoescht, Zeiss Filter Set #49 (ex G 365 nm, FT 395, em BP 445/50 nm); EGFP, Zeiss Filter
Set #44 (ex BP 475/50 nm, FT 500, em BP 530/50 nm).

3.4.5

Image analysis using CellProfiler.

The image analysis algorithm used by CellProfiler is customizable and contained within
a 'PIPELINE' that describes a series of image manipulation and evaluation steps, such
as reading the image, adjusting the intensity, and identifying objects. Each step has
several options. We found that the translocation ratio was generally robust, provided
nuclei were accurately identified. Using the image of Hoescht fluorescence and Otsu's
method of automatic thresholding, nuclei were identified and segmented using 3 class
thresholding. The middle class was assigned to background. Closely approximated
objects were separated using 'Laplacian of Gaussian' modeling, and touching nuclei were
divided using the 'shape' option. Nuclear regions were expanded by 2 y.m to generate
an enlarged region. The nuclear region was subtracted from enlarged region to generate
a ring surrounding the nucleus (surround). The diameter of the surrounding region was
chosen to be 2 ^m larger than the nucleus, within the range (1-3 ^m) used by previously
reported high content screens[i72,173]. The ratio of the median intensities of the nuclear
and surrounding region of the GFP or mCherry (as appropriate) image were collected
for every cell examined. Those cells falling below a threshold of intensity (10% of the
maximum intensity of the image) were discarded as 'untransfected'. Typically, 20-60
transfected cells from 15-30 images were examined for each experimental condition.
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34*6

Examination of Membrane Integrity via Cell Impermeable Dyes.

The loss of membrane integrity was examined via assaying nuclear fluorescence after
exposure to Sytox Blue (Invitrogen), a cell impermeant dye that fluoresces brightly when
complexed with DNA. Syto Orange 85 (also Invitrogen) was used as a cell permeable
counter stain. HeLa cells plated in glass bottom microtitre plates were exposed for 30
min at 37°C to x

dexamethasone labeled cationic miniature protein or peptide in

HKR buffer containing x

Sytox Blue and x

Syto Orange. Buffer without peptide

or containing xo pig/mL Saponin was used as negative and positive controls respectively.
After incubation cells were washed briefly in HKR buffer, and examined immediately
via epifluorescence microscopy (Zeiss Axiovert 200M). Sytox Blue fluorescence was vi
sualized using Filter Set 49, Syto Orange 85 was visualized using Filter Set 43. Images
were analyzed using ImageJ.

3.4.7

Competition binding of dexamethasone labeled miniature proteins or
peptides with Fluormone® for the glucocorticoid receptor.

Differences in the affinity of dexamethasone-labeled molecules for the human glucocor
ticoid receptor were assessed via competition binding. For this purpose, we employed
a Glucocorticoid Receptor Competitor Assay Kit (Invitrogen). Varying concentrations
of dexamethasone-labeled miniature protein or peptide (or dexamethasone as a control)
were suspended in 48 ^L Screening Buffer (xo mM NaP04, pH 7.4; 20 mM Na2Mo04, x
mM EDTA, 2% DMSO) and incubated with 2.5 nM FLUORMONE GSX and 4 nM recombi
nant human GR for 3 h in the dark at room temperature. Following incubation, the fluo
rescence polarization of each solution was measured on an Analyst AD plate reader (LJL
Biosystems). Each data point represents the average fluorescence polarization (± stan
dard deviation) of three separate experiments. Data were plotted as polarization (mP)
vs. Logfinhibitor] and fit to the following equation using GraphPad software (Prism):
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_
_ .
mP = Prrun -|

Pmax-Pirun
1 + 10((C]-^(^50))

where mP is the polarization of the sample, [C] is the concentration of the test compound,
Pmax is the polarization of the sample when no competitor is added, and Pmin is the
polarization that represents maximum competition.

3.4.8

Peptide Degradation.

Approximately 200,000 HeLa cells were treated with rhodamine labeled cationic minia
ture proteins and peptides as described for experiments using flow cytometry to measure
peptide uptake. These cells were pelleted in 96 well microtitre plates (300#, 3 min) and
lysed in 40 }iL RIPA buffer (150 mM NaCl, 50 mM Tris pH 7.4, 50 mM EDTA pH 7.4, 0.1%
SDS, 1% Triton X-100) on ice for 30 min. The insoluble material was cleared from the cell
lysate via centrifugation (io,ooog, 10 min) and 20 ^L of the supernatant was diluted into
400 }iL of 15% CH3CN in water. These samples were analyzed via reverse phase HPLC
(Shimadzu Instruments) fitted with a fluorescence detector and a C18 column (Poroshell
120 SB-C18, 2.7pm, 100 mm x 3 mm ID, Agilent; Fig. 3.8) or a C8 column (Kinetex C8,
2.6pm, 100 mm x 2.6 mm ID, Phenomenex; Fig. 3.9).

3.4.9

Resistance to Cathepsin Acid Proteases

50 pmol aPPR, 5.2r, 5.3s, TatR, or Arg8K were incubated with 5 pg cathepsin B, D, or L for
30 min at 37 °C in xo pL of 20 mM sodium citrate-phosphate buffer (pH 4.7) containing
150 mM NaCl. At the end of the incubation, the reaction was stopped by adding 40
pL of a solution containing a 84:15:1 ratio of water:EtOH:TFA before analysis by HPLC
(Shimadzu Instruments) fitted with a fluorescence detector and a C8 column (Kinetex
C8, 2.6pm, 100 mm x 2.6 mm ID, Phenomenex).
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34-10

Generation of Cytoplasmic Extracts using SLO

To generate cytosolic extracts, we first we verified that we could selectively release the
cytoplasmic contents of HeLa cells using the published procedures. 2 x 105 HeLa cells
were treated with 20 pg/mL SLO in PBS containing 5 mM DTT (20 min, 4 °C), washed
(three PBS washes, 150 pL each), and resuspended in 40pL PBS. To allow oligomerization
of membrane bound SLO and pore formation, cells were incubated at 37 °C for 15 min.
Cells were separated from cytoplasmic extracts by centrifugation (2 min x300g) and the
supernatant (cytoplasmic extract) retained.
To monitor the fraction of cells permeabilized ijopL of PBS containing ipM propidium iodide (PI), a marker of permeabilized cell membranes, was added to the cell pellet
following slow treatment and the cells examined by flow cytometry. Under these condi
tions, 85 to 89% of the cells accumulated PI, indicating that the plasma membrane had
been disrupted. To examine the contents of the cytoplasmic extracts, the insoluble ma
terial was cleared from the cytoplasmic extracts via centrifugation (io,ooog, 10 min) and
20 fiL of the supernatant was diluted into 40 JIL of 15% CH3CN and 0.1% TFA in water.
These samples were analyzed via reverse phase HPLC (Shimadzu Instruments) fitted
with a fluorescence detector and a C8 column (Kinetex C8, 2.6pm, 100 mm x 2.6 mm ID,
Phenomenex). To confirm that these conditions did not release material present within
lysosomes, 2 x 105 HeLa cells were treated with SLO at 4 °C, washed, resuspended in
PBS, and incubated at 37 °C for 15 min as described above. The cells were then pel
leted by centrifugation (2 min x300g) and the supernatant recovered, after which the
cell pellet was treated with detergent lysis buffer (RIPA buffer) to solubilize the mem
branes. Total cell lysate from an equal number of HeLa cells that were not treated with
SLO served as a positive control. These three fractions (total cell lysate, supernatant
from SLO treated cells, and the solubilized cell pellet) were then incubated with a so
lution containing 7.5 mM 4-nitrophenyl-N-acetyl-p-D-glucosaminide (Sigma-Aldrich) in
0.1 M citrate-phosphate buffer, pH 4.7. 4-nitrophenyl-N-acetyl-j3-D-glucosaminide is a
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chromogenic substrate for the lysosomal enzyme j3-hexosamididase which, via hydroly
sis, releases 4-nitrophenol whose presence can be spectrophotometrically monitored via
absorbance of 405 nm light.

3.4.11

Analytical Ultracentrifugation

Miniature proteins were dissolved in either PBS or HKR buffer at 60, 20, or 10 jiM con
centration and loaded into 6 chambered cells. Buffer blanks without peptide were used
as controls. The cells were loaded into the rotor, and spun in a Beckman XL-i analytical
ultracentrifuge with absorbtion optics at increasing speeds (36,000, 42,000, 50,000, and
60,000 rpm). Peptide sedimentation profiles were assessed at both 280 nm and 230 nm,
using a o.x mm step size for the scan position. In this way, scans were completed each
hour. The approach to equilibrium was monitored using the MATCH function of HETEROANALYSIS, in which the root-mean-square-deviation (rmsd) between successive scans
is calculated. Centrifugation at each speed was continued for a minimum of 6 hr, until
the rmsd was no longer decreasing, or until the rmsd was < 0.005 between successive
scans. At this point to rotational speed was increased or, after reaching equilibrium at
60,000 rpm, the run was stopped.
Data analysis began with the calculation of physical parameters. Solvent density,
p, was calculated using SEDNTERP, while partial specific volume 07) was calculated by
hand using the method of [163], making adjustments for the inclusion of the c-terminal
amide, as well as the presence (or absence) of a dexamethasone coupled to an N-terminal
lysine. The extinction coefficient for unlabeled miniature proteins was calculated directly
from the amino acid sequence[i74]. For dexamethasone labeled molecules, the absorb
tion of dexamethasone at 280 nm (863 M_1 cm-1) was added to the value calculated
from the amino acid sequence. The absorbance of dexamethasone labeled molecules and
unlabeled molecules at 230 nm was measured relative to the absorbance at 280 nm. The
molar extinction coefficient at 230 nm for dexamethasone labeled miniature proteins was
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determined using the relative absorbances: £230 = -A230

x

3^-

Next scans of sedimentation profiles obtained after the sample arrived at equilibrium
were loaded into HETEROANALYSIS. Scan points representing the solution column were
selected manually. In some cases, individual points were excluded because of spurious
increases in absorbtion. Refitting the data with these points included, led to no change
in the calculated association constant of the final model. To examine the presence of a
self-association, data were first fit (using non-linear least-squares regression) to a model
representing the sedimentation of a single ideal species:

C(r) = C(r 0 )e M ( 1 _ ^~~^ ! ^ + B 0
where M is the molecular weight, RT is the product of the universal gas constant and
the temperature in kelvin, C(ro) is the apparent concentration of the sedimenting species
at an arbitrary reference point in the solution column (the miniscus), and C(r) is the
apparent concentration at radius r, and Bo is an arbitrary adjustment for the background
absorbtion of the solution. The usuable range of absorbance represents the limits of
accurate measures of C(r), usually taken to be between 0.1 and 1, acceptable fits generally
show rmsd < 0.01 and small Bo, usually < 0.01. A best-fit molecular weight significantly
higher than the calculated molecular weight is evidence of self-association.
Next, to examine possible association states of the studied molecule, the data are fit
to a general model of reversible two-state (monomer, n—mer) self-association, using the
observation that at equilibrium, the law of mass action specifies that the concentration
of multimer at all points along the column is satisfies K a • C%(r) = C n M(r), where C m (r)
and C„M(r) are the concentrations of the monomer and n—mer, at radius r respectively.
The model is specified by the following equation

Ctotaiir) = C m (ro)e M { l - V p ) ^i^ +K a ( C m ( r 0 ) ) n + B 0
in which all variables are specified, with the exception of K a , Bq and n.
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Finally, the sedimentation profiles are fit to an integer association state using the
general two-state monomer-to-n—mer model above, except n is fixed at the integer closest
to the best fit n found when n was allowed to vary continuously.
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Figure 3.19: HPLC analysis of labeled peptides used in this study.
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Name
aPP
2.1
2.2
3.2
4.2
4.3
5.2
5.3
6.3
Name
aPPF
2.1F
2.2F
3.2F
4.2F
4.3F
5.2F
5.3F
6.3F
Name
sPPR
4.2R
4.3R
5.2R
5.3R
raf1
Args"
Name
appDex

4.2Dex
4.3d®*
5.21*"
5.3De»
ratf**
Arg8Dex

Sequence

Formula

Calc (+m/z) Meas

IS
M06ISI
-196H 293N560MSI
-I97H295N57O60S1

"200H308N63O56S1
-200H3O9N67O57S1

4399
4427
4441
4469
4496
4497
4538
4524
4567

Fluorescein Labeled Sequences

Formula

Calc (+m/z) Meas

GPSQPTYPGDDAPVEDURFYNDLQQYLNWTRHRYCflu-NH2

C215H302N55O65S1

GPSQP"TYPGDDAPVEDLJRFYNDLQRYLNWTRHRYCflu-NH2

NH2
-NH2
GPSQPTYPGDDAPVRDLIRFYRDLRRYLNVVTRHRYCflu.NH2
GPSQPTYPGDDAPVRDLRRFYRDLRRYLNWTRHRYCfuj-NH2

C216H306N57O64S1
C217H308N58O64S1
C218H312N59O63S1
C219H317N63O61S1
C219H316N62O62S1
C221H323N64O60S1
C220H321NMO60S1
C220H322N68O60S1

4729
4758
4777
4800
4827
4828
4870
4855
4989

RJiodamine Labeled Sequences

Formula

Calc (+m/z) Meas

-NH2
KRhodGPSQPTYPGDDAPVRDL[RFYRDLQRYLNWTRHRY-NH2
KRhodGPSQPTYPGDDAPVEDLIRFYRDLRRYLNWTRHRY-NH2

C223H323N57O66S2

GPSQPTYPGDDAPVEDLIRFYNDLQQYLNVVTRHRYCACRTYL
GPSQPTYPGDDAPVEDLIRFYNDLQRYLNVVTRHRYCATKYL

FLH2
-«H2
GPSQPTYPGDDAPVEDQRFYRDLQQYLNWTRHRYC^-NHZ
GPSQPTYPGDDAPVEDLIRFYRDLQRYLNWTRHRYCACETV,-NH2
GPSQPrTYPGDDAPVRDLIRFYRDLQRYLNWTRHRYCACE'VL-NH2
GPSQFrTYPGDDAPVEDURFYRDLRRYLNWTRHRYCA»L»L.NH2
GPSQPTYPGDDAPVRDLIRFYRDLQRYLRWTRHRYC^-NHZ

C20lH31lN63O5«Sl

GPSQPTYPGDDAPVRDLIRFYRDLRRYLNWTRHRYC^-NH?
GPSQPTYPGDDAPVRDLRRFYRDLRRYLNWFRHRYCACET L

* -NH2

GPSQPTYPGDDAPVEDURFYRDLQQYLNWTRHRYCfuj-NH2
GPSQPTYPGDDAPVEDURFYRDLQRYLNWTRHRYCflu-NH2
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Figure 3.20: Mass spectral data obtained for miniature proteins and peptides in this
work.
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Chapter 4

Cationic Miniature Proteins Reach
The Cytoplasm By Escaping From
Early Endosomes
4.1 Background
While there is little controversy that under certain conditions some 'cell-penetrating' pep
tides can reach the cytoplasm of cells when added to the surrounding media, very little
is considered accepted regarding how they do so. Some models for cytoplasmic access
focus on direct plasma membrane permeation[175], perhaps aided by ion-pair guided
diffusion[i2i, 120], the creation of inverse micelles[io6], membrane disruption[176, 125,
142], or peptide self-association[i77] with the possible formation of pores[i78,179]. Oth
ers advocate that peptides cannot cross the plasma membrane directly, but rather enter
the cell through endocytic mechanisms[i8o]. Within this latter category, there has been
much debate on the particular mechanism of endocytosis that is responsible for the in
ternalization of the peptide into endosomes, however, by itself, the mechanism by which
peptides arrive in endosomes sheds little light on how escape to the cytoplasm may oc
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cur. Nevertheless, because the field has focused so much on this question, a brief review
is pertinent.

4.1.x

Endocytic mechanisms of cationic peptide internalization

The mechanistic understanding of endocytosis has become much more sophisticated
in the last 10 years, but with this sophistication comes some confusion. Several re
cent reviews have restored order through the reinstatement of (in some cases, previously
developed[i8i]) experimental classification schemes[i82,183]. Three types general endo
cytosis should be considered, the first two being phagocytosis and endocytosis mediated
by clathrin or other coat proteins, the third being endocytosis by mechanisms that are
not characteristic of the first two types. Whether nascent endosomes require dynamin
activity to separate from the plasma membrane is also a useful feature for classification.
Phagocytosis is generally a process limited to phagocytic cells (macrophages, den
dritic cells, etc), is stimulated by the presence of large (i.e. > 0.5

[184]) particles,

involves large changes in the distribution of the plasma membrane and is sensitive to
cytochalasin-D, an inhibitor of actin polymerization. The process may involve dynamin,
but its activity in this case is not due to membrane scission[i85], but rather its ability
to recruit Rab5 to the phagocytic cup[i86, 187]. Because cationic miniature proteins are
monomeric in solution, the role of phagocytosis is less important in these studies.
Clathrin-mediated endocytosis is the major mechanism by which coated vesicles me
diate endocytosis[i88, 189]. The clathrin coat is responsible for the initial deformation
of the plasma membrane (a clathrin coated pit), and adaptor proteins recruit cargo into
the growing bud. Transferrin is constitutively internalized by this pathway[i90, 137]
as is activated epidermal growth factor receptor[139]. Fluorescently labeled versions of
these proteins have been used as markers for vesicles originating from this pathway.
Caveolin is a second protein localized to the interior leaflet of plasma membrane invagi
nations, and appear to be the preferential site of entry for certain virus, including SV-
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4o[i9i/192,193], however its role in mediating endocytosis is being reevaluated[x94,195,
196].

The other major coat proteins, COPI, COPII, are generally not active at the plasma

membrane[i97]. Dynamin is absolutely required for clathrin mediated endocytosis[i98,
199].

The study of endocytosis mechanisms capable of internalizing small particles with
out the participation of clathrin is a growing field, with a rapidly increasing number of
example pathways. In general, these pathways are induced by the inhibition of other
pathways, making them more difficult to study. Mayor and Pagano[x82] suggest seg
regating these pathways into those that relying on either RhoA, Cdc42, or Arf6, with
the latter two being independent of dynamin activity. Importantly all three of these
pathways seem to be sensitive to perturbations in the lipid C0ntent[200, 201], and in par
ticular depletion of cholesterol[202], from the plasma membrane. Cholesterol depletion
decreases (but does not completely inhibit) clathrin mediated endocytosis[203, 204].
Taken together the following experimental results are expected. Small cargo can en
ter via mechanisms that are (1) dependent on dynamin, (2) dependent on dynamin and
cholesterol, or (3) independent of dynamin (and dependent on cholesterol). Clathrin me
diated endocytosis falls into the first catagory, and cargo taken up by this route should
colocalize with fluorescently labeled transferrin or EGF. The latter two catagories segre
gate RhoA and Arf6 pathway (2) from the Cdc42 pathway (3). Inhibition of dynamin
clathrin mediated endocytosis may stimulate clathrin independent pathways, so this
must be kept in mind when interpreting experimental findings. Peptide uptake may
occur by one or several of these mechanisms.

4.1.2

Trafficking of endocytosed peptide

While there may be a multitude of internalization pathways, a great simplification is
achieved by the finding that the itineraries of these pathways converge. In the case
of clathrin, once the clathrin coated pit pinches off from the plasma membrane, the
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phosphoinositides on the membrane are rapidly metabolized from phosphoinositol-4,5bisphosphoate (PI(4,5)P2) to PI3P, and leading to the recruitment of the small GTPase
Rab5[205]. Rab5+ endosomes undergo homotypic fusion (i.e. fusion with other Rab5+
vesicles) to form the compartment known as the 'early endosome'[2o6, 207]. While
the molecular events regarding Rab5 aquisition are less well understood in the case
of other endocytic pathways, the cargo internalized by the Cdc42 dependent[2o8] and
Arf-6 dependent[209, 210] pathways are delivered to Rab5+ vesicles. This has led to the
current hypothesis that all endocytosed cargo is delivered to the Rabs+ early endocytic
compartment.
The early endosomal compartment serves as a cargo sorting station[i8i]. Sorting
molecular cargo destined to return to the cell surface takes place by actin dependent
spatial segregation into specialized domains within the early endosomes[2ii]. These
domains then bud off to form tubular/vesicular structures that fuse with the plasma
membrane, recycling the cargo back to the cell surface. In the absence of material being
recycled to the plasma membrane, early endosomes exchange Rab5 for Rab7[2i2, 2x3]
forming 'late endosomes', which then fuse with lysosomes[x40, 214]. Cargo destined for
other cellular locales travel through late endosomes, but the mechanism by which they
are selectively delivered to their destinations is not understood.

4.1.3

Reaching the cytoplasm

As stated above cationic miniature proteins may reach the cytoplasm by crossing the
plasma membrane directly or by escape from an intracellular vesicle. The ability of
cationic miniature protein 5.3 to access the cytoplasm in the absence of endocytosis
would strongly suggest the ability to cross the plasma membrane directly. In the absence
of this ability, the question arises, from which endosomal population does 5.3 escape? It
would also be useful to compare the identify to the answer for 5.3 to the vesicles from
which other peptides can escape to the cytoplasm.
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The molecular character of endosomes changes with their maturation. As endosomes
mature, they increase in byouant densitiy, acquire different lipid and protein compo
nents, and increase their lumenal concentration of acid. The ability to reach the cyto
plasm may be induced by one or more of these bulk physicochemical properties, or it
may be due to the recruitment of a protein ligand that facilitates the specific exist of 5.3
or another cell penetrating peptide.

4.2 Results
Three limiting models have been invoked to explain the trafficking of cationic peptides
and proteins across the plasma membrane and into the cytosol. The first posits that high
local concentrations of positively charged peptides cause membrane disruption[i25]. We
previously confirmed that the integrity of the cell membrane is not disrupted in the
presence of

1

pM cationic miniature protein (see Fig.

3.4, on

invokes ion-pair guided passive membrane diffusion[i2i,

page 46). A second model

X20];

while the third model

invokes endocytosis followed by endosomal release (vide infra). We sought to distinguish
between remaining models in two ways. First, we asked whether rhodamine labeled
cationic miniature proteins are taken up into the same vesicles as transferrin, a classic
marker of endocytosis; finally, we asked whether inhibitors of endocytosis block the
uptake of these same molecules.

4.2.1

Cationic miniature proteins traffic first into endocytic vesicles

To distinguish between the two remaining mechanisms of uptake, we began by treating
HeLa cells with rhodamine labeled miniature proteins in the presence of AlexaFluor-488transferrin (Tf488) and quantifying colocalized fluorescence using confocal microscopy
(Fig.

4-x).

Transferrin, a protein whose trafficking serves as a predominant model for

the study of endocytosis[x83] is rapidly internalized from the plasma membrane into
endocytic vesicles[x39, 2x5]. Thus, the localization of rhodamine labeled miniature pro
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tein in transferrin positive vesicles would suggest that those vesicles were endocytic in
nature, originating from the plasma membrane. We incubated HeLa cells at 37°C for 30
min with Tf488 (25 nM) and 1 }iM 4.2s, 4.3s, 5.2s, 5.3^ TatR or Arg8R. The cells were
washed with media, and labeled with Hoescht (to visualize DNA). Images were then
obtained by spinning disk confocal microscopy without fixing the cells in order to avoid
the possible release of peptide from intracellular vesicles that can occur following fixa
tion by treatment with formaldehyde or methanol[i27, 140]. As expected, when excited
with 488 nm light, HeLa cells treated with Tf488 showed small, discrete areas of green
fluorescent signal distributed throughout the cytosol. Addition of aPPR led to little or no
red fluorescent signal and little or no change in the green signal due to Tf488, confirming
earlier results (Fig. 3.3) that aPPR is not taken up efficiently by HeLa cells. In contrast,
HeLa cells treated with 1 jiM 4-2R, 4.3s, 5.2^, 5.3s, TatR or Arg8R showed bright red flu
orescent puncta throughout the cytosol in a distribution that overlapped with the green
fluorescence

seen with Tf488 and at levels that qualitatively reproduce the trends detected

by flow cytometry (Fig. 3.3). With one exception, the fluorescent

signal from Tf488 and

the rhodamine labeled molecules were highly correlated (R/m,Rhodamine - 0.619 - 0.779),
suggesting that transferrin and cationic miniature proteins/peptides 4.2s, 5.2R, 5.3R, TatR
or Arg8R are taken up into the same endocytic compartments. Miniature protein 4.3s is
also taken up into a transferrin+ compartment, but the correlation (R^ss,Rhodamine = 0.493)
is lower, possibly because the uptake is low (Fig.3.3).
To assess whether peptide trafficking is affected by fluorophore

identity, we directly

compared the intracellular distributions of rhodamine and fluorescein tagged versions
of aPP, 4.2, 4.3, 5.2, and 5.3, as well as Tat and Arg8 (Fig. 4.2). While HeLa cells treated
with 1 fiM aPPF and aPPR exhibited little or no fluorescence,
with rhodamine and fluorescein

those treated simultaneously

labeled variants of either 4.2, 4.3, 5.2, or 5.3 contained

bright puncta with substantial correlation between the rhodamine and fluorescein sig
nal. Overlap was also observed after treatment with rhodamine and fluorescein

labeled

versions of Tat as well as Arg8. The per-pixel correlation between rhodamine and fluo-
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Figure 4.1: Colocalization of alexaFluor-488-transferrin Tf488 with rhodamine labeled miniature proteins. Perfect colocalization is
characterized by a Pearson's R value (R) equal to 1, while R values near o represent little or no colocalization. The correlation value
observed when cells were treated with both Tf488 and alexa-fluor-546-transferrin is 0.905. Rhodamine labeled cationic miniature
proteins and alexa-546-transferrin are shown in red, Tf488 is shown in green, Hoescht 33342 (nucleus) is shown in blue.

rescein intensities was found to be highly significant for all cationic miniature proteins
(R > 0.68) as well as for Arg8 (R = 0.756), and Tat (R — 0.631). These results confirm
that these molecules traffic to similar locations in the cell regardless of fluorescent label
location or identity, and recapitulate the similarity in the quantitative analysis of peptide
uptake above (Fig. 3.3, on page

43).

Next, we asked whether small molecules known to inhibit endocytosis would block
the uptake of rhodamine labeled miniature proteins. Dynasore[2i6]is an inhibitor of the
GTPase dynamin, a protein whose activity is required for clathrin mediated endocytosis
(CME)[2i7], pinocytosis[2i8, 219], as well as caveolin mediated endocytosis[i9i]. De
pleting cellular cholesterol through treatment with methyl-/3-cyclodextrin (M/5CD) also
inhibits these three processes[i9i, 204]. Endocytic pathways that continue despite loss of
dynamin activity and depletion of cellular cholesterol[2i7] depend on actin remodeling,
a process inhibited by addition of N-ethyl-isopropyl amiloride (EIPA)[22o]. Addition of
EIPA does not affect the uptake of CME ligands such as transferrin[22o]. To test the in
volvement of these pathways in the uptake of cationic miniature proteins, we pretreated
HeLa cells for 30 min with 80

dynasore, 5 mM Mj6CD or 50 }iM. EIPA before adding

1 jiM 4.2R, 4-3R, 5-2r, 5-3r, TatR, Arg8R or aPPR. Peptide uptake was allowed to pro
ceed for 30 min at 37°C in the presence of inhibitor; the cells were subsequently washed
and visualized by confocal microscopy (Fig. 4.3). The presence of dynasore completely
blocked the uptake of 4~2R, 4.3s, 5.zR, 5-3R, as well as TatR and Arg8R; suggesting these
molecules are taken up in a dynamin-dependent fashion. M/5CD completely blocked the
uptake of 4-2R, 4.3s, 5-2R, 5.3^ and TatR, but not Arg8R. Surprisingly cellular uptake of
Arg8R was increased in the presence of M/3CD, leading to diffuse fluorescence through
out the cytosol, a pattern not seen in the absence of the inhibitor (see Fig. 4.1 and Fig.
4.3). The presence of EIPA also dramatically reduced the uptake of cationic miniature
proteins, as well as TatR and Arg8R. The results with Arg8R notwithstanding, these
data support the contribution of various endocytic pathways to the uptake of cationic
miniature proteins and peptides, and not a model based on passive diffusion.
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Figure 4.2: Colocalization of rhodamine and fluorescein labeled cationic miniature pro
teins. HeLa cells were treated with 1
rhodamine and fluorescein cationic miniature
protein or peptide for 30 min at 37°C before being washed and imaged using confocal
microscopy. HeLa cells treated with aPPR and aPPF show low fluorescence. The remain
ing molecules show high fluorescence, and molecules sharing the same sequence (but
different labels) show high degrees of overlap, with R > 0.68. Scale bars are 20 }im.
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Figure 4.3: Uptake of cationic miniature proteins is inhibited by treatments the block endocytosis. HeLa cells were preincubated
in media (ctrl) or media containing 80 pM dynasore, 5 mM M/3CD, or 50 pM EIPA before the addition of 1 jiM of the indicated
rhodamine labeled peptide or Tf488 for 30 min. Cells were then washed, labeled with Hoescht (nucleus, blue) and visualized
without fixation by confocal microscopy.

4.2.2

Cytoplasmic access requires active endocytosis

In many cases, cationic proteins/polypeptides showing cellular uptake by flow cytom
etry remain trapped in endosomes and fail to reach the cytosol[i28]. This raises the
possibility that cytoplasmic access does not depend on endosomal escape, but rather
direct diffusion through the plasma membrane. Having shown that cationic miniature
proteins enter endocytic vesicles, we sought to test whether their cytoplasmic accumu
lation was the result of endosomal escape or diffusion acros the plasma membrane. We
were mindful of the fact that exchanging the fluorescent rhodamine label for dexametha
sone could alter the physical properties of the molecule as well as the manner in which
it trafficked in cells. Because inhibitors of endocytosis prevented the entry of cationic
miniature proteins into endocytic vesicles, we wondered whether treatment with these
same inhibitors would also block cytoplasmic access. Such a finding would support the
conclusion that diffusion across the plasma membrane, in the absence of active endocy
tosis, is an ineffective route to the cytoplasm.
Having identified 5.3°" as a cationic miniature protein showing significant cytoplas
mic access, and hence significant increases the nuclear-to-cytoplasmic translocation ratio
of GR-GFP, we set out to determine the pathway by which cytosolic access was achieved.
Having previously shown that pharmacologically inhibiting endocytosis blocked uptake
of 5-3r (Fig. on the preceding page), we first asked whether inhibiting endocytosis in
the same manner also blocked the ability of 5.3°®* to reach the cytoplasm. HeLa cells
transfected with GR-GFP were pre-treated for 30 min with the aforementioned inhibitors
prior to the addition of either 1 jiM dexamethasone (positive control), aPPDex (negative
control), 5.3°", TaiPex, or Arg8Dex for 30 min at 37°C (Fig. 6). The cells were then washed
and imaged to measure the translocation ratio. None of the endocytosis inhibitors altered
the GR-GFP translocation ratio calculated for cells treated with aPPDex, which remained
low after treatment. However, all three inhibitors reduced, to background levels, the
GR-GFP translocation ratio calculated after treatment with 5.3°", 1atDex, or Arg8Dex.
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Neither EIPA nor dynasore altered the increase in the translocation ratio calculated after
treatment with dexamethasone, but M/5CD reduced this increase by 53%. This effect may
be due to direct complexation of free dexamethasone by M/3CD[22i].
Because endosomes contain very small volumes, their internal pH is exquisitely sen
sitive to the activity of proton pumps, including V-ATPases; acidification begins almost
immediately upon scission of endosomes from the plasma membrane, as their lumen
no longer communicates with the surrounding media. Bafilomycin is a potent inhibitor
of the V-type ATPase[222, 223], and its addition to culture media prevents endosomal
acidification[i23, 222]. To ask whether low vesicular pH was required for cytoplasmic
escape, we pretreated HeLa cells expressing GR-GFP with 200 nM bafilomycin for 1 h be
fore exposure to 1 jiM dexamethasone, 5.3°", TatDex, Arg8Dex or aPPDex (Fig. on the next
paged). Treatment with bafilomycin did not alter the effect of dexamethasone or aPPDex
on the translocation ratio, consistent with the understanding that dexamethasone freely
diffuses into the cytoplasm and that aPPDex never enters endocytic vesicles. The increase
in translocation ratio seen after cells were exposed to 5-3Dex, however, was completely
blocked by the presence of bafilomycin (p — 1.4 x 10~n). Bafilomycin also blocked the
increase in translocation ratio seen after treatment with TatDex (p = 5.3 x 10-n) or
Arg8Dex (p = 8.2 x 10~6). Thus, while 5-3Dex, and to a slightly lesser extent TatDex and
Arg8Dex, induce robust translocation of GR-GFP, they fail to do so in the absence of endosome acidification. This finding further supports the model that these molecules do
not penetrate the plasma membrane directly, but rather escape to the cytoplasm from
acidified endocytic vesicles.

4.2.3

Escape to the Cytoplasm from Early Endosomes

Cell surface protein and lipids are constitutively internalized to form cytoplasmic en
dosomes. One canonical route, typified by transferrin and its receptor, is internaliza
tion via clathrin-coated pits, after which the surrounding vesicle membrane under-
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Figure 4.4: Inhibition of endocytosis blocks cytoplasmic access. Translocation of GR-GFP
after treatment with 1 pM Dex, 5-3Dex, TatDex, Arg8Dex, or aPPDex in the presence
(gray) or absence (black) of various small molecule inhibitors. Inhibitors of endocyto
sis included (a) 80 pM dynasore, (b) 5 mM methyl-B-cyclodextran (MBCD), (c) 50 jiM
EEPA. (d) Translocation ratio after treatment with cationic miniature proteins and 200
nM bafilomycin . *p < 0.05; * * *p < 0.001; ANOVA with Bonferroni post test.
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goes rapid modification resulting in dissociation of the clathrin coat and acquisition
of Rab5[2i5, 205]. The presence of Rab5 recruits cellular factors required for vesicle fu
sion and maturation, including the phosphotidyl inositol 3-OH kinase, Vps34 [224]. The
resulting early endocytic compartment mixes via homotypic fusion with other Rab5+
vesicles[225, 226], and delivers cargo to other cellular locales through the budding off
of transport vesicles[2ii] or Rab conversion[2i2, 2x3]. While transferrin is recycled to
the cell surface, other cargo, including low density lipoprotein, epidermal growth factor
(EGF)[227,

228] and

several types of viruses[i40, 229,

196]

are delivered to late endo

somes, marked by Rab7, for eventual degradation in lysosomes[i40, 227]. To character
ize the intracellular route taken by cationic miniature proteins to the cytoplasm, we first
looked for overlap of 5.3R, TatR and Arg8R with markers of endocytic uptake and GFP
tagged Rab proteins. Then, using small molecule inhibitors and dominant negative Rab
variants, we tested the cellular activities required for 5.3°", TatDex and Arg8Dex to enter
the cytoplasm.
To characterize the pathway by which 5.3°^ moves from the exterior of the cell to
the cytosol, we began with the observation that 5.3^ colocalizes with transferrin (Fig.
4.1), a substrate known to internalize into Rab5+ vesicles[2X5]. To ask whether

5.3s

was also present in Rab5+ vesicles, HeLa cells were transfected with GFP-Rab5 and
treated for 30 min with 1 jiM 5.3^. When these cells were examined by confocal mi
croscopy, 66% of the rhodamine signal overlapped with the signal from GFP-Rab5, con
firming that 5-3R is present in Rab5+ vesicles (Fig. 4.5a). To test whether trafficking of
5-3R could be arrested at the Rab5 stage, we overexpressed a GTPase-inactive Rab5 mu
tant, Rab5(379L[225], that blocks delivery of cargo to late endosomes and arrests vesicle
maturation[2i2, 229, 140, 225]. Observation of HeLa cells overexpressing Rab5®79L-GFP
and treated with 5.3s showed that nearly all (99%) of the miniature protein localized to
enlarged GFP+ endosomes (Fig. 4.5b), suggesting that arresting early endosome matu
ration also arrests trafficking of 5.3** at the Rab5+ stage. Similar results were seen with
Arg8R and TatR (Fig 4-5d-i). Because Rab5 vesicles rapidly deliver their cargo to down

xo6

stream vesicles[2i2], we also evaluated colocalization of 5.3s with Rab7-GFP (Fig. 4.5c).
HeLa cells transfected with Raby-GFP and treated with 5.3s as above, showed that a
large fraction (87%) of the rhodamine signal was located in the Rab7-GFP compartment,
confirming that 5.3s enters both early (Rab5+) and late (Rab7+) endosomes. We found
no overlap between 5.3s, TatR, or Arg8R and galT-GFP[23o, 231], a marker of the golgi
(see Fig. 4.6).
To ask whether 5.3 uses intracellular trafficking pathways that are distinct from the
pathway used by miniature proteins that do not reach the cytoplasm, we directly com
pared the intracellular trafficking of 5.3 to other cationic miniature proteins, as well as
to Tat and Arg8 (Fig. 4.7). Examiniation of HeLa cells treated simultaneously with x
5.3s and 4.2F, 4.3^ or 5.2^ showed strong correlations (R > 0.68) between the fluores
cence intensity due to the two miniature proteins present in the sample. There was also
strong correlation between the fluorescence intensity of 5-3F and Arg8R when applied to
the same sample (R = 0.631), suggesting that 4.2, 4.3, 5.2, 5.3, and Arg8, all occupy the
same or similar sets of intracellular compartments. This conclusion was also supported
by the observation that >90% of total integrated fluorescence from 5.3 overlapped with
the other miniature protein or peptide present in the sample.
The case was different for the comparison of 5.3s and TatF: the correlation between
the per-pixel fluorescence intensities was lower (R = 0.554). Substantial amounts of
green fluorescence

from TatF remained visible on the cell surface (arrowheads, Fig. 4-7d),

whereas no red fluorescence

from 5.3^ was visible at these same locations. In addition,

there is a noticeable absence of the small fluorescent

vesicles containing 5.3 from the

zoomed image that appear in images from the other samples. In contrast, small vesicles
are present in the image field, however they contain only TatF and not 5.3s. Conse
quently, only 32.1% of the green fluorescence

originates from locations occupied by 5-3R,

whereas 92.1% of the red fuorescence originates from locations occupied by TatF. Thus,
the addition of TatF reduces the presence of 5.3s is small (but not large) endocytic vesi
cles. This may be due to competition for a limited number of binding sites on the cell
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Figure 4.5: Miniature protein 5.3s enters via endocytosis into Rab5+ vesicles before traf
ficking to Rab7+ vesicles. HeLa cells transfected with the indicated GFP fusion protein
(panels a - i) were treated with 1 pM 5.3R (panels a-c), TatR (panels d-f) or Arg8R (panels
g-i) before being washed and imaged by confocal microscopy. Colocalization of 5-3R,
TatR and Arg8R with Rab5-GFP is moderate (panels a, d, g) but can be increased by ar
resting Rab5 maturation via overexpression of Rab5®79L-GFP. (panels b, e, h). 5-3R, TatR
and Arg8R are delivered to Rab7+ endosomes (panels c, f, i).
surface.
These data suggest that during the first 30 min after treatment, 5-3R, TatR, and Arg8R
follow a shared path through Rab5+ and then Rab7+ vesicles and provide a starting point
to ask which, if any, of these trafficking events are required to reach the cytoplasm.
To identify the point or points along the endocytic pathway at which these three
molecules escape to the cytsosol, we blocked vesicle maturation by overexpressing Rab5®79LGFP and assayed for GR activation following treatment with 5-3Dex, TatDex, and Arg8Dex
(Fig. 4.8). In this setting cytosolic localization was assessed via dual color microscopy
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Figure 4.6: Cell permeable cationic miniature proteins are not found within the Golgi.
HeLa cells were transfected with galactosyltransferase tagged to GFP, (a marker of the
Golgi) before plating in 96 well glass bottom plates and growth overnight. The me
dia was replaced with HKR buffer containing (a) x pM 5.3s, (b) TatR or (c) Arg8R and
incubated at 37°C for 30 min, after which the cells were washed and imaged. No red flu
orescence (arrowheads) was found within Golgi areas identified by high levels of green
fluorescence. The fraction of rhodamine signal overlapping green signal (R G G) within
the golgi region (boxed in white) is low (less than 0.1). Selected vesicles showing red flu
orescence are indicated with white arrowheads. None overlap with green fluorescence
signal. Scale bars are 20 ^m.
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using an orthogonally labeled GR-mCherry. This experiment allowed us to ask whether
inhibiting Rab5 vesicle maturation also blocked the ability of 5.3Dex, TatDex, and Arg8De*
to reach the cytosol. Control experiments reveals that the observed translocation ratio
of untreated HeLa cells expressing Rab5G79L-GFP or Rab5-GFP and GR-mCherry is near
unity, as expected (Fig. 4.8a). This remained unchanged after treatment 30 min with 1
aPPDex (translocation ratio = 1.32 ± 0.07, 1.25 ± 0.04, respectively); however, these
values increased substantially after treatment for 30 min with 1 jiM of dexamethasone
(Rab5-GFP expressing cells, 2.24 =t 0.15; Rab5Q79L-GFP expressing cells, 2.45 ± 0.21; Fig.
4.8a). Treatment with 5.3°** results in translocation ratios that are similar regardless of
whether cells were transfected with GTPase-inactive Rab^79L or wild-type Rab5- Analo
gous findings are observed when cells were treated with Arg8Dex: the translocation ratios
calculated are independent of Rab5 activity (1.59 ± 0.12 vs 1.60 ± 0.09). By contrast, overexpression of Rab5Q79L blocked the ability of TatDex to reach the cytoplasm (1.26 ± 0.03
vs 1.57 ± 0.04, p = 0.0057) indicating that Tat escapes inefficiently from Rab5+ vesicles.
These findings suggest that 5.3 and Arg8 escape to the cytoplasm from Rab5+ vesicles,
but Tat escapes from later along the endocytic pathway.
To confirm the finding that Rab5 vesicle maturation is dispensable for cytoplas
mic access, we treated cells with 200 nM wortmannin, a pharmacologic inhibitor of
phosphoinositide-3-OH kinase (PI3K) and an agent widely used to block the maturation

Figure 4.7 (following page): Cationic miniature protein 5.3 shares an overlapping intracel
lular distribution with other cationic miniature proteins, Tat and Arg8. HeLa cells treated
with 5.3K and (a) 4.2F, (b) 4.3^ (c) 5.2F, or (d) TatF labeled cationic miniature proteins
show high degrees of overlap. A single confocal slice is shown (left). Zoomed images
(boxed white area on the wide-field image) are shown for individual fluorescence chan
nels and an overlay (right), (e) 5»3F also shows substantial overlap with Arg8R. Pearson's
correlation coefficient (R) calculated between red and green pixel intensities is shown.
The correlation is high (R > 0.63) for all cases except for 5.3s and TatF (R — 0.554).
In this case, there is an absence of fluorescence from 5.3 in small vesicles that is seen
in the other images. TatF also shows fluorescence remaining on the plasma membrane
(arrowheads), whereas 5.3s does not. Calculation of overlap using Mander's coefficient
reveals that 92.1% of the red fluorescence overlaps green, whereas only 32.1% of green
fluorescence overlaps red.
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Rab5-GFP

•INo inhibitor
•IWortmannin

Rab5-GFP

^

%- + ' *

V
••

+ 200 nM Wortmannin

Figure 4.8: Cationic miniature protein 5.3 escapes from early endosomes. (a) Transfection
with Rab5Q79L-GFP does not block the increase of translocation ratio seen after treatment
with dexamethasone, 5.3°", or Arg8De*, but decreases the translocation ratio measured
after treatment with Tat0" (p = 0.005). (b) HeLa cells treated with 200 nM wortmannin
for 30 min before treatment with 1 fiM dexamethasone, 5.3°", TatDev, Arg8°", or aPPDex
for 30 additional min in the continued presence of the drug. Wortmannin decreased the
translocation ratio measured after treatment with TatDe* {p = 8.1 x 10~15 ) and Arg8Dev
(p — 2.3 x 10-5). The effect of wortmannin on the distribution of Rab5 is assessed by
confocal microscopy, (c) Rab5-GFP expressing HeLa cell, (d) Rab5-GFP expressing HeLa
cell in the presence of 200 nM wortmannin for 30 min. ns, not significant; *p < 0.05;
* * p < 0.01; * * * p < 0.001, ANOVA with Bonferroni post test.

112

of Rab5+ vesicles[226, 224]. This concentration of wortmannin was sufficient to induce
tubulation and enlargement of Rab5+ vesicles (Fig. 4-8d), observations consistent with
the inhibition of their maturation. As can be seen in Fig. 4.8b, this treatment blocked the
increase in translocation ratio seen after treatment with TatDex and Arg8Dex by 72% and
77%, respectively. In contrast, the translocation ratio seen after treatment with 5-3Dex in
the presence or absence of wortmannin was similar (2.36 ± 0.08 vs 2.76 ± 0.10), confirm
ing the ability of 5.3°" to escape from Rab5+ vesicles. The difference between results
obtained after wortmannin treatment and overexpression of Rab5^79L-GFP may be ex
plained by recent results that wortmannin may arrest vesicles in an early Rab5+ state,
prior to the recruitment of Rab5 effectors[226, 205]. Taken together, these data suggest
that arresting vesicle maturation inhibits the cytosolic access of both TatDex and Arg8Dex,
but that 5.3°" is capable of leaving these earliest vesicles and reaching the cytoplasm.

4.2.4

Arginine topology affects protonation state transitions during endocytic
acidification.

While the above data suggests that cationic miniature protein 5.3 can access the cyto
plasm by escaping from Rab5+ vesicles, the chemical basis for why this sequence pos
sesses this property is unknown. Comparisons between the sequence of 5.3, a miniature
protein that is cell penetrating, and the sequences of aPP, 4.2, 4.3, and 5.2, miniature pro
teins which do not enter the cytoplasm, provide an opportunity to examine the effects
of sequence changes on side-chain protonation states and structure. Data presented in
figure 3.2 show that arginine containing variants of miniature proteins have similar cir
cular dichroism spectra, suggesting a conserved fold. Large scale structural differences
among these miniature proteins are thus unlikely to be the basis for their differing prop
erties. Furthermore, the number of arginine residues alone, 5 versus 4, is not sufficient
to explain the differences in cell permeability.
We wondered whether side-chain protonation states could be altered by changes in
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neighboring amino acids, and whether these differences may explain differences in the
ability to access to the cytoplasm. Importantly, for the guanidinium side chain group
of arginine pKa « 12, indicating that this side chain is nearly always protonated in the
buffered (pH

=7.4)

aqueous environment surrounding the cell, and shifting to the more

acidic environment of the endosome is unlikely to alter this state. Therefore we instead
looked to see if there were acidic side chains whose pKa was shifted such that in they
would undergo a protonation state transition within the endosome.
To begin, we submitted the amino acid sequence of aPP,

4.2, 4.3, 5.2

and

5.3

to

PEPSTR[232] an online structural prediction tool that returns predicted structures based
on sequence using hidden Markov modeling. These structures were essentially identical
to the X-ray structure of aPP[i29] bolstering our expectation that these sequences fold
in a similar manner. Repeating this structural prediction using another method based
on neural networks (available online at Geno3D[233]) showed the ten lowest energy pre
dicted conformations of 5.3 based on sequence had an overall RMSD of

0.49A

from aPP,

providing further reassurange that the backbone fold is maintained between these two
miniature proteins. We compared the sequences of aPP and 5.3 and identified residues
that are altered in 5.3. These are GIU15, Asn22, Gln25, and Gln26, while Argi9 remains
unchanged. Finally, we used the software tool PKATOOL[234], an algorithm that predicts
amino acid pKa based on three dimentional structure, to search for interactions that al
ter side-chain pKa in aPP and
predicted structure of

5.3

5.3

using the published X-ray structure of.aPP and the

obtained from PEPSTR. First, we analyzed the side-chain in

teractions within aPP looking for interactions that would be destroyed by the arginine
substitutions in 5.3. Second, we asked whether any new interactions would be created
by the arginine subsitutions within

5.3.

Third, drawing on our experimental evidence

that blocking endosomal acidification blocks cytoplasmic access, we asked which, if any,
residues within
pH

7.4

5.3

would be predicted to undergo a protonation state transition from

(the pH of the extracellular medium) to pH

4

(the pH of the lysosome). This

range is likely overly broad as our data supports a model in which 5.3 can escape from
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the less acidic early endosome.
Our analysis (shown in Fig. 4.9) reveals that within aPP, GIU15 interacts strongly
with both Aspi6 (kT/e = 1.003) and Argi9 (kT/e — -1.078). In fact, these interaction
energies are the second and third largest in magnitude within the molecule, and two
of only three interactions with |fcT/e| > 1. These residues are also positioned closely in
space, with Glui5-Aspi6 side chains within 2.8A of each other, and Glui5-Argi9 distance
o

to be ~3-2A (Fig. 4.9a). Using PKATOOL, the charge state of each of these amino acids
is shown as a function of pH in figure 4.9b. Both GIU15 and Aspi6 begin to undergo
protonation as the pH drops below 7. One might suspect that the close apposition of
the glutamic acid with the basic arginine stabilizes this amino acid in the deprotonated
state, however when a third titratable species is added close by (Aspi6) the overall effect
is less obvious. Modeling this effect with the PKATOOL shows a reciporical relationship
in pKa purterbation. That is to say, that modeling an increased pKa of Aspi6, results in
a decreased pKa of

GIU15, and

vice versa (Fig. 4.9c). Because amino-acid side chains far

from their equilibrium may not behave according to Henderson-Hasselbalch transitions,
the concept of pKi/2 is introduced as the pH at which the acid is half protonated. This
value is similar to the value of the pKa but does not imply knowledge of protonation
state occupancy at other pH conditions, because, especially in protein, other acid-base
transitions may be taking place. The pK\/2 of Aspi6 is predicted to be at pH = 4.2,
changing GIU15 -» Arg (i.e. modeling this residue as a base with pKa =

13,

see figure

4-9d) changes this value to pKi/2 = 3.4, indicating stabilization of the deprotonated
species. Further changing Asn22 -» Arg (shown in gray) increases this difference, with
the predicted pK1/2 = 3.1. Thus arginine substitutions at residues

15

and 22 is likely to

stabilize Aspi6 in the deprotonated state giving 5.3 a decreased positive charge at similar
pH than would be present with an alternative spatial arrangement of charges.
Next we examined the modeled structure of

5.3

obtained from PEPSTR. Interaction

energies examined in PKATOOL revealed no new interactions with energies |fcT/e| > 1.
The energies of interaction of Glui5-Aspi6 and Glui5-Argi9 previously seen were now
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Figure 4.9: Modeling arginine interactions reveals subtly perturbed side-chain pK„'s,
but these interactions stabilize deprotonated carboxylic acids, making protonation state
transitions less likely to occur during endosomal acidification, (a) X-ray structure (PDB
code lPPT) showing Aspi6, GIU15, and Arg19 are closely approximated in space, (b)
Modeled pH titration of Aspi6, GIU15, and Argi9 with color coding as shown in panel
a, Aspi6 and GIU15 become protonated (and neutrally charged) as the pH drops from
7 to 3. (c) The pK„ of GIU15 and Aspi6 are linked. GIU15 as more basic (shift shown
by green arrow) stabilizes the deprotonated form of Asp16 resulting in a lower modeled
pKa (blue arrow). The modeled pKa of Argi9 remains unchanged, (d) Modeling GIU15
and Asn22 as arginine residues is predicted to increase the acidity of Asp16 and Argi9(e) His34 is the only residue predicted to become protonated within the early endosome.
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decreased bewteen both Argi5 and Aspi6 (k T / e = —0.252) as well as Argi5 and Argi.9
(kT/e = 0.347). Decreasing the threshold for significant interactions |JcT/e| > 0.5 re
vealed a continued interaction between Asp23 and Aspi6 whose strength is increased
slightly from kT/e = 0.402 to kT/e = 0.501, as well as new interactions present be
tween Arg25 and Tyr2i (kT/e = —0.504) as well as Arg26 and Asp23 (kT/e = —0.578).
Searching for side-chains whose pKa's were perturbed by molecular interactions revealed
that residues Argi.5, Aspi6, Argi9, Asp23, and Arg25 showed the greatest deviation of
\ApKa\ > 0.5, while Tyr2i and Arg26 were perturbed less. Given that cationic miniature
protein 5.3 can escape from the moderatly acidic early endosome, we searched for effects
that would shift protonation state changes seen under acidic conditions to a more neutral
pH range. Removing the influence of Argi9 lead to a decrease in the predicted acidity
of Aspi6 from pKi/2 = 3.6 to pKi/2 = 4.2 suggesting that Argi9 stabilizes the deproto
nated form of Asp16. A similar effect is seen on Asp23, where removing Argi9 resulted
in a predicted shift of pKi/2 = 3.9 to pKi/2 = 4.2. Removing either or both Arg25 and
Arg26 also was predicted to destabilize Aspi6 and Asp23, though the predicted effect is
smaller. These results suggest that stabilization of the deprotonated forms of Aspi6 or
Asp23 is improved in the presence of the additional arginine residues, and that arginine
leads to a more acidic transition rather than one that would take place at a more neutral
pH.
Finally, we asked whether any side chains of 5.3 would be predicted to undergo
signficant protonation state changes between pH 8 and pH 5, roughly the pH transition
that takes place between the extracellular space and the late endosomal compartment.
The only residue of 5.3 that is predicted to undergo a protonation state transition within
this range is His34 with a predicted pK\/2 = 5.9, which transitions from a neutral to a
positively charged species (Fig. 4-9e). The interaction energy prediction matrix shows
that this residue possesses only minimal interactions with other residues. Removing
either Argi.5, 19, 22, 25, 26, or 33 resulted in increases in the calculated pKt/2 from -5.9
to 6.0-6.1. While this difference is small it is consistent with an intuitive model in which
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the presence of each of additional arginines destabilizes the protonated form of the side
chain. His34 in the context of aPP is predicted to have a pKi/2 = 6.0.
None of the above outlined predictions identify a new protonation state transition
that is predicted to take place during acidification of the early endosome. This analysis
views miniature proteins aPP and 5.3 in isolation, without taking into account known
interactions with cellular proteins and proteoglycans. Based on this limited view, my
analysis is unable to identify particular side chain protonation states that predicted to be
altered between the extracellular pHj environment and the and more acidic endosomal
environment, any residue within 5.3 whose transition is predicted to take place in the
early endosome where the analogus residue in aPP is not also predicted to do the same.
Of course, this does not exclude the possibility that such a change does, in fact, take place
- interactions between either aPP or 5.3 with cellular proteins could alter the individual
pKa s of the peptide side chains, leading to the formation of a critical protonated species
that is able to escape from the endosome. Alternatively, the activity of the endosomal
V-type ATPase could be required for escape for a separate reason. The activity of V-type
ATPase contributes to a trans-membrane electrochemical gradient, leads to the influx of
chloride, across chloride channels, and participates in numerous other physiologic ion
movements. One or several of these features could regulate the activity an endosomal
protein required for the cytoplasmic escape of cationic miniature proteins.

4.3

Discussion

Coupling a new assay for cytosolic localization with live cell corifocal microscopy al
lowed us to compare the structural determinants required for efficient endocytosis with
those required for cytoplasmic escape. This comparison revealed that contrasting struc
tural determinants control endocytic uptake and endosomal release. Uptake is favored
by clustered a-helical arginine side chains, whereas release requires a more dispersed
arginine array.
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I found that inhibiting endocytosis blocked the ability of miniature protein 5.3, Tat,
and Arg8 to reach the cytoplasm. This finding strongly suggests against their ability to
penetrate the plasma membrane directly, and argues for a model in which their pathway
to the cytoplasm to begin with internalization into cellular vesicles followed by escape to
the cytosol. I found that the internalization of 4.2,4.3,5.2,5.3 as well as Tat and Arg8 was
dependent on the activity of dynamin, and was sensitive to cholesterol depletion. My
finding that the small molecule EIPA blocked internalization suggests that reorganization
of the actin cytoskeleton is also involved in the internalization of these miniature proteins
and peptides. Internalization by pinocytic pathways such as the RhoA and Arf6 pathway
and clathrin mediated endocytosis are consistent with these observations. Accordingly,
after 30 minutes of internalization I observed the presence 5.3s, TatR and Arg8R within
Rab5+ vesicles, followed by Rab7+ vesicles.
Previous studies on the trafficking of various viruses[3i] and clostridial toxins, such
as botulinum and anthrax toxin[32], have revealed multiple potential release points along
the endocytic pathway. JC virus[229], SV40I196], and HIV-i[235], all require transport
beyond early Rab5+ endosomes to gain cytosolic access. Requirements for cytosolic
access have been extensively studied in the case of SV40: transport from Rab5+ to Rab7+
endosomes precedes transport to the golgi, and the endoplasmic reticulum where the
virus crosses the endoplasmic reticulum membrane to access the cytosol. Botulinum and
tetanus toxins, however, seem to require only low pH to insert into the membranes[236],
and thus cytoplasmic access can occur in the absence of endosome maturation.
Inhibiting Rab5 vesicle maturation either through the addition of wortmannin or ex
pression of a Rab5 dominant negative mutant had no effect on the ability of 5.3 to reach
the cytoplasm, indicating that 5.3 enters into and efficiently escapes from early (Rab5+)
endosomes. In contrast, Tat and Arg8, which are also present in Rab5+ vesicles, require
Rab protein exchange or the activity of Vps34 (and possibly the subsequent recruitment
of Rab5 effectors) in order to reach the cytoplasm. Inhibition of endosomal acidifica
tion through the addition of bafilomycin inhibited cytosolic access of 5.3, Tat and Arg8.
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Thus, the pathway uncovered here for miniature protein 5.3 bears the greatest resem
blance to that described for botulinum toxin and anthrax toxin, which also escape from
early endosomes and require low pH to do so. The pathways followed by Tat and Arg8
require downstream events or further endosomal acidification that is achieved after the
early endosome. This distinction implies the existence of alternate signals favoring early
versus late endosomal release. Identifying these signals and understanding their mech
anistic basis may allow researchers to target molecules to a desired delivery pathway,
increasing the rapidity and ease with which designed peptides may access the cytosol.
This understanding may also shed light on the fundamental nature of the permeability
barrier presented by lipid bilayers.
Miniature protein 5.3, with the lowest charge density, was released at the earliest
common point along the endocytic pathway, whereas Tat and Arg8, which carry higher
charge density, were released later. The differences in arginine/lysine number and ori
entation in 5.3, Tat, and Arg8 can affect side chain pKa, and thus overall charge at a
given pH, as well as affinity for as-yet-unidentified cellular targets. It is possible that the
distinct arginine array in 5.3 favors the formation of a critical protonated species in the
moderately acidic environment of the early endosome (pH « 6.5), whereas the lower pH
present in lysosomes may be required to generate an equivalent state for Tat and Arg8.
It is equally possible that the discrete arginine array in 5.3 represents an export signal for
a cellular machinery that has yet been identified.

4.4
4.4.1

Experimental Methods
Cell Culture and Transfections.

HeLa cells (ATCC, Manassas, VA) were grown in T-75 culture flasks containing Dulbecco's Modified Essential Medium (DMEM, Gibco Cat. #11995-065) supplemented with
10% FBS, and 100 U/mL each Penicillin and Streptomycin. Transient transfections were
performed using Fugene 6 or XtremeGene HP (Roche) using the protocols recommended
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by the manufacturer. Plasmids encoding Rab5-GFP and Rab5Q79L-GFP were gifts from
Pietro DeCamilli. A plasmid containing Rab7-GFP was a gift of Qing Zhong (Addgene
plasmid # 28047). A plasmid containing GalT-EGFP was a gift of Jeniffer LippincottSchwartz (Addgene plasmid # 11937). A plasmid containing the glucocortcoid receptor
fused to EGFP (pK7-GR-GFP) was a gift of Ian Macara (Addgene plasmid # 15534).

4.4.2

Colocalization of miniature proteins with Alexa-488-transferrin and RabGFP fusions.

To examine the colocalization of rhodamine labeled miniature proteins or peptides with
Alexa-488-transferrin (Tf488), HeLa cells were plated (200 pL, 104 cells /well, 96 well glass
bottom plates, Matrical) the day prior to experiments. The media was replaced with 150
fiL Hepes-Krebs-Ringer's (HKR) buffer (140 mM NaCl, 2 mM KC1, 1 mM CaCl2, 1 mM
MgCl2, 10 mM Hepes pH 7.4) containing 1 pM miniature protein or 25 nM Alexa-488transferrin (Molecular Probes) and the cells incubated at 37°C for 30 min. The cells were
then rinsed twice with 200 |iL HKR buffer and nuclei were labeled by overlaying 200 (iL
HKR containing 300 nM Hoechst 33342 (Molecular Probes Cat. # H3570) for 5 minutes.
Images of cells were acquired using a PerkinElmer LiveView spinning disk confocal mi
croscope fitted with a 60 x 1.2 NA objective. Colocalization with Rab-GFP fusions was
examined in an analogous way using HeLa cells transfected with the appropriate expres
sion plasmid.
Colocalization between rhodamine and fluorescein labeled miniature proteins and
peptides, or between rhodamine labeled miniature proteins and markers of endocytosis
was completed using confocal microscopy. Live cell confocal microscopy was conducted
using a PerkinElmer LiveView spinning disk confocal microscope fitted with heated mi
croscope enclosure (maintained at 37°C), a 6ox 1.2 NA objective, laser illumination, a
Nipkow CSU-iX spinning disk, and a Hammamatsu CS9100 EMCCD camera operated
using Velocity software. Alexafluor-488-transferrin was detected using a 488 nm laser
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and a 520 nm long pass filter; tetraethylrhodamine and Alexafluor-546-transferrin were
detected using a 546 nm laser line and a 580 nm long pass filter, Hoescht 33342 was de
tected using a 405 nm laser line and a 450 nm long pass filter. Images were processed for
presentation by using the 'subtract background' option and linear contrast adjustments
in Image J. All adjustments were applied uniformly to the entire image. Colocalization
analysis was performed using the JACOP plugin5, available on the ImageJ website. The
fraction of rhodamine signal overlapping with EGFP signal (R e G) was calculated using
Mander's coefficient and automatic thresholding. Pearson's correlation coefficient (R)
was also obtained using the JACOP plugin.

4.4.3

Effects of inhibitors on cell uptake.

HeLa cells grown for 24 h in glass bottom plates were incubated with HKR buffer, or
HKR buffer containing 80 pM dynasore, 50 pM N-ethyl-isopropyl-amiloride, or 5 mM
methyl-(3-cyclodextrin for 30 min at 37°C prior to the addition of 1 pM rhodamine-labeled
miniature protein or peptide (Tat and Arg8). The cells were washed twice with DMEM,
the nuclei labeled with Hoescht, and images acquired as described above for colocaliza
tion experiments.

4.4.4

Effect of inhibitors on cytoplasmic access by dex-labeled miniature pro
teins or peptides.

HeLa cells transfected with pKy-GR-GFP for 24 - 36 hr were plated (104/well in 200
pL) the day prior to experiments in 96 well glass bottom plates (Matrical). The media
was replaced with HKR buffer containing 300 nM Hoescht and the cells incubated for
30 min at 37°C. The media was then replaced with 150 pL HKR buffer or HKR buffer
containing 1 pM dexamethasone labeled cationic miniature protein or peptides or 1 pM
dexamethasone as a positive control. The cells were incubated for a further 30 min at
37°C before epifluorescence imaging using a Zeiss Axiovert 200M microscope fitted with
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a mRM digital camera, a 63 x 1.3NA PlanApo objective and an EXFO-Excite illumination
source. Dual color epifluorescence images were acquired using the following filter sets:
Hoescht, Zeiss Filter Set #49 (ex G 365 nm, FT 395, em BP 445/50 nm); EGFP, Zeiss Filter
Set #44 (ex BP 475/50 nm, FT 500, em BP 530/50 nm).
To examine the effects of various inhibitors on the ability of dexamethasone labeled
cationic miniature proteins to activate the glucocorticoid receptor, HeLa cells were transfected and plated as above. Thirty minutes prior to the addition of dexamethasone la
beled cationic miniature proteins and peptides the media was replaced with HKR buffer
containing 300 nM Hoescht and 80 nM dynasore, 50 jiM N-ethyl-isopropyl-amiloride or
5 mM methyl-6-cyclodextrin and the cells incubated for 30 min at 37°C after which 1 jiM
dexamethasone labeled miniature protein or peptide was added. Uptake was allowed to
proceed for an additional 30 min at 37°C before analysis by epifluorescence images as
described above. Images were analyzed to determine the ratio of nuclear to cytoplasmic
GR-GFP using CellProfiler (see § 3.4.5 on page 84).

4.4.5

pGR-mCherry vector construction.

The full length glucocorticoid receptor (NR3C1) was subcloned into pmCherry-Ni (Invitrogen), generating a C-terminal fluorescent protein fusion, by amplifying the gene from
PK7-GR-GFP

using PCR primers containing Saci and BamHi restriction sites. The ampli

fied PCR product was digested and ligated into the multiple cloning site of pmCherry-Ni
digested with the same restriction enzymes.

4.4.6

Requirement of Rab5 activity for the ability of peptides to reach the
cytoplasm.

HeLa cells transfected for 24 - 36 hr with pGR-mCherry and either Rab5-GFP or Rab5®79LGFP were plated (104/well in 200 JJL) the day prior to experiments in 96 well glass bot
tom plates (Matrical). The cells were washed with HKR buffer and the nuclei labeled
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using Hoescht as above. Then

150

jiL HKR buffer or HKR buffer containing

amethasone labeled cationic miniature protein or peptides or

1

1

p.M dex

pM dexamethasone as

a positive control was overlaid into the well. The cells were incubated for a further
min at

37°C

30

before imaging. Cells that had been cotransfected with EGFP fusions were

identified via their characteristic pattern of green and red fluorescence. To evaluate the
extent of GR activation, epifluorescence images were obtained as described above, except
the fluorescence of pGR-mCherry was also visualized using Zeiss Filter Set
545/25

nm, FT

570,

em BP

605/70

#43

(ex BP

nm). Images were analyzed to determine the ratio of

nuclear to cytoplasmic GR-mCherry using CellProfiler.

4.4.7

Statistical Analysis.

Comparisons within groups were made using ANOVA. Pairwise comparisons within
groups were made using Bonferroni's post-test after finding a significant difference us
ing ANOVA. P-values are adjusted for the number of comparisons (using Bonferroni's
method[237,

238, 239])

so that the family-wise error rate, FWER = 0.05 as follows. Fol

lowing the determination of a statistically significant difference using ANOVA, the signif
icance of a given pairwise comparison from among set containing J groups is calculated
using the £-stastistic. Let p(t, df) be the significance of a two-tailed t-test between two
groups with degrees of freedom df. Then the signiciance of the difference using Bonfer
roni's method p' between two groups from a family containing J groups is distributed
as

p' = p ( t , N - J ) where t is the test statistic from the between group comparison, N is the number of
degrees of freedom from the ANOVA analysis and / is the number of groups in the
family. A critical feature of this method of correction is that the number of groups in
the family from which the pairwise comparison is drawn has a significant effect on the
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the significance of the result, p'. An alternative way of reporting Bonferroni corrected
P-values is to alter the significance level a at which a test is considered significant. In
this case, a is usually set so that a! = ot • j.^iy and the null hypothesis H° is rejected if
p{t,N — J) > a'. As an example using this second method, a single pairwise comparison
from a family containing 6 members would need p < 0.003 to be considered significant.
This alternative method is functionally equivalent to the one used here. The advantage
of reporting p' is that these values are intuitively understandable and the false-discovery
rate (in the alternative method, the example comparison with p < 0.003 has a false
discovery rate of 0.05). One caveat to our approach is that in the case of negative results
(i.e. when H° is not rejected), it is possible to find p' > 1, which is unphysical. This
oddity is generally acceptable, because in these cases, the exact value of the significance
of the test in unimportant.
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